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Abstract 
Lead is a toxic metal which widespread use has resulted in environmental contamination and 
significant health problems. It is a cumulative toxicant that affects multiple body systems, including the 
cardiovascular, hematopoietic, reproductive, and renal systems. Lead is also a well-known neurotoxin, 
inducing changes in neurogenesis, neurodegeneration and changes on glial cells. These changes in the 
molecular and cellular processes lead to cognitive and behaviour alterations, particularly during 
developmental phases, persisting throughout the lifetime.  
Most of the studies that have been performed in both humans and animals were focused in a 
continuous chronic exposure to lead. This lead exposure causes behavioural changes, cognitive 
impairment and hypertension associated with sympathoexcitation, baroreceptor reflex hyposensitivity 
and increased chemoreceptor reflex sensitivity. But the effects of an intermittent lead exposure are 
scarse and standardized animal models are non-existent. This pattern of exposure has been increasing 
in the last years due to migrations, implementation of school exchange programs and/or residential 
changes.  
Therefore, the overall purpose of this work was to evaluate lead effects on mammal’s 
physiology along different profiles of lead exposure, including a new animal model of intermittent low-
level lead exposure.  
Animal models of lead exposure were developed by replacing the tap water of seven-day 
pregnant Wistar females with 0.2% (p/v) solution of lead acetate. After being weaned at 21 days, rat 
pups, both sexes, were divided into 3 groups of lead exposure: long-term (exposure from foetal period 
until 28 weeks of age), short-term (exposure from foetal period until 12 weeks) and intermittent 
(exposure from foetal period until 12 weeks, lead-free period until 20 weeks and a second exposure 
between 20 and 28 weeks of age).  
At 12, 20 and 28 weeks of age, behavioural tests were performed for anxiety (Elevated Plus 
Maze Test), locomotor activity (Open Field Test), spatial working memory (Y-Maze) and episodic long-
term memory (Novel Object Recognition test) assessment. Blood pressure (BP), electrocardiogram 
(ECG), heart rate (HR) and respiratory frequency (RF) were recorded at the same timepoints in the acute 
experiment. Baroreflex gain (BRG), chemoreflex sensitivity (ChS), cardiovascular variability were also 
evaluated.  
Immunohistochemistry studies for neuronal nuclear antigen (NeuN), Synaptophysin (Syn), 
ionized calcium binding adapter molecule-1 (Iba-1) and Glial fibrillary acidic protein (GFAP) stainings 
were performed in brain slices, and confocal imaging acquired and stainings quantified at dentate gyrus 
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(DG) of the hippocampus. Blood lead levels were assessed by atomic absorption spectroscopy and 
metabolic evaluation of all groups was done using metabolic cages. A control group of Wistar rats 
without lead exposure, of both sexes, with the same number of individuals, underwent the same 
protocol and were evaluated in the same time points. Student T-test and one-way ANOVA with Tukey’s 
multiple comparison between means were used (significance p<0.05) for statistical analysis. 
Our data showed a clear association between lead exposure, hypertension and 
cardiorespiratory reflexes impairment, without heart rate changes, independently of the type of lead 
exposure profile. We also demonstrated for the first time that lead intermittent exposure causes 
adverse health effects, i.e, hypertension, sympathetic overactivity, increased chemoreflex sensitivity 
and baroreflex impairment, similar to a chronic exposure, however less pronounced. In fact, at 28 
weeks, PbI group, the intermittent animal model of lead exposure developed, had a less severe 
hypertension when compared to the long-term exposure group (PbP), which might suggest that the 
duration of Pb exposure is more relevant than the time of exposure. Moreover, the effect on diastolic 
blood pressure produced by lead exposure was more evident than that of systolic blood pressure.  
Lead exposure from foetal period until 12 weeks of age causes long lasting hypertension and 
chemoreceptor reflex dysfunction even after a 16 weeks period without exposure. However, the 
clearance of lead promoted an improvement in baroreceptor reflex function, with repercussions on 
blood pressure values, since these values decreased, but did not reached the normotensive values.  
Regarding the autonomic data, in our study, the overactivity of the sympathetic nervous 
system, evaluated by the LF band, is concomitant with baroreceptor reflex impairment and/or 
hypertension. This means that the sympathetic nervous system may be involved in the modulation of 
the baroreceptor reflexes responses or in the hypertension development due to lead exposure.  
Concerning the effect of lead at behavioural level, all groups exposed to lead, evaluated in the 
three different time points, had behavioural changes, namely anxiety, hyperactivity and/or long-term 
memory impairment and molecular changes in the hippocampus region, more specifically, reactive 
astrogliosis and microgliosis were detected, indicating the presence of neuroinflammation. However, 
these alterations seem to reverse after lead abstinence for a certain period (single exposure) and are 
enhanced when a second exposure occurs (intermittent exposure), along with a synaptic loss.  
In summary, this study shows, that exposure to lead during the developmental phase can alter 
the normal course of development, with lifelong health consequences. Since all exposed Pb groups had 
the same route of exposure (i.e. exposure to lead by water) and the same dose and, despite the 
different time of exposure, all were exposed to lead since foetal period until adulthood, the most 
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susceptible period to adverse health effects. Therefore, we can conclude that the different effects of 
lead toxicant between groups mainly depends on the total duration of lead exposure.  
This comparative study brings new insights on the environmental factors that influence nervous 
and cardiovascular systems during development, which can help creating public policy strategies to 
prevent and control the adverse effects of Pb toxicity. 
Key-words: lead toxicity; autonomic dysfunction; hypertension; behavioural and cognitive 
changes; gliosis  
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Resumo 
A identificação de agentes potencialmente tóxicos e a avaliação dos seus efeitos sobre o 
organismo humano constituem um tema importante de saúde pública. O chumbo encontra-se neste 
grupo de agentes, sendo bastante utilizado em todo o mundo, devido às suas propriedades únicas, 
como a alta maleabilidade, baixo ponto de fusão, suavidade, ductilidade e resistência à corrosão. O 
vasto uso deste metal pesado em indústrias, como a automóvel, cerâmica, de tintas e do plástico levou 
ao aumento da quantidade de chumbo livre no ambiente e a sua ocorrência nos sistemas biológicos, 
devido à sua natureza não biodegradável. 
A toxicidade do chumbo, como resultado da sua ingestão, inalação ou por contacto direto, 
mesmo em pequenas quantidades, pode evocar efeitos adversos irreversíveis em várias funções do 
corpo, afetando principalmente os sistemas cardiovascular (sendo uma das causas da hipertensão, 
promovendo aterosclerose, trombose, arteriosclerose e doenças cardiovasculares), hematopoiético, 
reprodutivo e renal. O chumbo é também uma neurotoxina já bem estudada, que induz alterações na 
neurogénese, nas células gliais e neurodegeneração. Estas alterações nos mecanismos celulares e 
moleculares, quando ocorrem durante as fases de desenvolvimento, provocam alterações cognitivas e 
comportamentais, que persistem durante toda a vida.  
Em termos de classificação, dois tipos de toxicidade de chumbo podem ser definidos: a 
toxicidade aguda, que geralmente ocorre pela exposição ocupacional a níveis elevados de chumbo, 
sendo esta bastante incomum, e a toxicidade crónica, uma exposição a níveis baixos de chumbo, mais 
comum no ambiente familiar. A maioria dos estudos realizados até à data em seres humanos e animais, 
focam-se na exposição crónica contínua e/ou permanente ao chumbo e nas consequências adversas 
na saúde deste tipo de exposição. Existem já, vários modelos animais descritos para a exposição 
contínua a níveis baixos de chumbo. No entanto, em determinadas situações, como nas migrações, nos 
programas de intercâmbio escolar e/ou nas mudanças residenciais, a exposição intermitente ao 
chumbo pode ocorrer, mas os estudos disponíveis em seres humanos são escassos e os modelos 
animais padronizados inexistentes para este tipo de exposição, que tem vindo a crescer 
exponencialmente nos últimos anos. 
Posto isto, o objetivo geral deste trabalho consistiu em avaliar os efeitos de diferentes perfis 
de exposição a níveis baixos de chumbo na fisiologia de ratos Wistar, incluindo o desenvolvimento de 
um novo modelo animal de exposição intermitente a chumbo. 
Os modelos animais de exposição ao chumbo foram desenvolvidos substituindo a água dos 
biberões das fêmeas Wistar grávidas de sete dias por uma solução de acetato de chumbo a 0,2% (p/v). 
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Após os 21 dias de desmame, as crias, de ambos sexos, foram divididas em 3 grupos de exposição ao 
chumbo: de longo prazo (PbP - exposição do período fetal até às 28 semanas de idade), de curto prazo 
(Short-term  PbS - exposição do período fetal até às 12 semanas, com abstinência ao chumbo até às 
28 semanas) e intermitente (PbI - exposição do período fetal até 12 semanas, seguida por um período 
sem chumbo até 20 semanas e uma segunda exposição entre 20 e 28 semanas de idade). Em três 
diferentes pontos temporais (12, 20 e 28 semanas de idade), os diferentes grupos de animais foram 
sujeitos a testes comportamentais, para a avaliação dos níveis de ansiedade (EPM), da atividade 
locomotora (OFT), da memória espacial de trabalho (Y-Maze) e da memória episódica de longo prazo 
(NOR). Para avaliação dos parâmetros fisiológicos nos diferentes pontos temporais, os animais foram 
sujeitos a uma experiência aguda, onde foram registados os seguintes parâmetros: pressão arterial 
(PA), eletrocardiograma (ECG), frequência cardíaca (FC) e frequência respiratória (FR). Nesta 
experiência também se avaliaram os reflexos baro- e quimiorrecetores e obtiveram-se registos para a 
análise da variabilidade da FC e da PA sistólica. Após o término da experiência aguda, os animais foram 
sacrificados e os cérebros extraídos para estudos de imunohistoquímica em secções coronais, nas quais 
se analisou a morfologia das células e se quantificou a perda neuronal (neuronal nuclear antigen - 
NeuN), a astrogliose (Glial fibrillary acidic protein – GFAP) e a microgliose (ionized calcium binding 
adapter molecule-1 - Iba-1), bem como alterações na transmissão sináptica (Synaptophysin – Syn) no 
girus dentado do hipocampo. Os níveis de chumbo no sangue foram avaliados por espectroscopia de 
absorção atómica e a avaliação metabólica realizada através do uso de gaiolas metabólicas. Um grupo 
controlo de ratos Wistar sem exposição ao chumbo, de ambos os sexos e com o mesmo número de 
indivíduos, foi submetido ao mesmo protocolo e foi avaliado nos mesmos pontos temporais (12, 20 e 
28 semanas de idade). Para a análise estatística foi utilizado o teste T de Student e a análise de Variância 
(ANOVA) unidirecional com o teste post-hoc de Tukey, considerando-se significativas diferenças com p 
< 0,05. 
Os resultados deste estudo mostram que, independentemente do tipo de perfil de exposição 
ao chumbo, existe uma associação clara entre exposição a chumbo, hipertensão e diminuição do ganho 
do barorreflexo, sem alterações de frequência cardíaca.  
Também demonstramos, pela primeira vez, que uma exposição intermitente a chumbo 
provoca efeitos adversos para a saúde, como hipertensão, hiperatividade simpática, aumento da 
sensibilidade quimiorreflexa e diminuição do ganho do barorreflexo, efeitos adversos semelhantes ao 
de uma exposição crónica permanente (PbP), porém menos pronunciada. De facto, às 28 semanas, o 
grupo PbI, o modelo animal intermitente de exposição ao chumbo desenvolvido, apresentou uma 
hipertensão menos grave em relação ao grupo de exposição de longo prazo (PbP), o que pode sugerir 
que a duração da exposição ao chumbo é mais relevante do que o tempo de exposição. Além disso, o 
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efeito da exposição ao chumbo sobre a pressão arterial diastólica foi mais evidente do que sobre a 
pressão arterial sistólica. A exposição ao chumbo, desde o período fetal até as 12 semanas de idade, 
provoca hipertensão e disfunção quimiorreflexa duradoura, mesmo com um período de 16 semanas 
sem exposição. No entanto, a abstinência do chumbo promoveu uma melhoria na função barorreflexa, 
com repercussões nos valores da pressão arterial, uma vez que estes valores diminuíram, apesar de 
não atingirem os valores de normotensão. 
Em relação à avaliação autonómica, os dados indicam que quando existe um aumento do tónus 
simpático, avaliado pela banda LF, este é concomitante com disfunção barorreflexa e/ou hipertensão 
arterial. Isso significa que o sistema nervoso simpático deve estar envolvido na modulação da resposta 
barorreflexa ou no desenvolvimento da hipertensão decorrente da exposição ao chumbo.  
Relativamente ao efeito do chumbo a nível comportamental, todos os grupos expostos ao 
chumbo, avaliados nos diferentes pontos temporais, apresentaram alterações comportamentais, 
nomeadamente ansiedade, hiperatividade e / ou défices de memória a longo prazo, bem como 
alterações moleculares, mais especificamente, astrogliose e microgliose reativa, que indicam a 
presença de neuroinflamação. No entanto, estas alterações parecem reverter após a abstinência do 
chumbo durante um determinado período (PbS - exposição de curta duração), sendo mais evidentes 
quando ocorre uma segunda exposição a chumbo (PbI - exposição intermitente), levando mesmo a 
perda sináptica mais pronunciada. 
Em resumo, este estudo mostra, que exposições a chumbo durante as fases de 
desenvolvimento podem alterar o seu curso normal, com consequências adversas para a saúde que 
podem persistir para toda a vida. Uma vez que todos os grupos expostos a chumbo tiveram a mesma 
via de exposição (isto é, exposição ao chumbo através da água) e a mesma dose e, apesar do tempo de 
exposição diferente, todos foram expostos ao chumbo desde o período fetal até a idade adulta, período 
em que são mais suscetíveis a efeitos adversos na saúde. Portanto, podemos concluir que os diferentes 
efeitos tóxicos do chumbo entre os grupos dependem principalmente da duração total da exposição ao 
chumbo. 
As novas evidências obtidas por este estudo comparativo permitem-nos contribuir para o 
esclarecimento sobre os fatores ambientais que influenciam os sistemas nervoso e cardiovascular 
durante o desenvolvimento, o que pode ajudar a criar estratégias de políticas públicas para prevenir e 
controlar os efeitos adversos da toxicidade do chumbo. 
Palavras-chave: toxicidade do chumbo; disfunção do sistema nervoso autónomo; hipertensão; 
alterações comportamentais e cognitivas; gliose 
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1  INTRODUCTION 
Lead 1 (Pb, from the Latin plumbum) is a post-transitional metal which compounds are mostly 
found in the +2-oxidation state.  
The low melting point and ductility, the high density and the inertness to oxidation, combined 
with the relative abundance, easiness of extraction and low cost2 justifies its leading position in human 
usage for more than 8000 years. In 2014, ten million tonnes of lead have been handled, over half of it 
in recycling processes3. Lead is heavily used in batteries production, pewters, construction, bullets and 
shotguns, plumbing, ceramics, weights, solders, fusible alloys, radiation shielding and leaded gasoline3 
but also in jewellery, pigments, stained glass, lead crystal glassware, toys, cosmetics, pesticides and 
traditional medicine, all of which have resulted in substantial introductions of free lead into the 
environment forming leaded dust and soils, contaminating water and air1,3,4and, overall, generating 
significant environmental pollution together with human and public health issues in many parts of the 
world5,6 (Figure 1). In fact, and regarding human and animal health, the particle size and the route of 
exposure are the impact factors of lead absorption that is inversely proportional to these features. 
Nevertheless, the nutritional status (fat and caloric intakes; phosphorus, copper, zinc and especially 
iron and calcium levels, all affecting lead absorption), fasting/fed status (fasting humans or animals 
absorb much larger fractions than their fed counterparts), health, and age of the individual also account 
for lead negative biological effects1,5,7.  
There are also intraspecies differences regarding lead toxicology. For human subjects, children 
absorb more lead into the blood when compared to adults1,8 In fact, adults, typically absorb up to 20% 
of ingested inorganic lead after a meal and up to 60-80% after a big period of hunger while children 
absorb about 50% of ingested lead after a meal and up to 100% on an empty stomach1. Exposure to 
lead dust (by the respiratory route) may elicit an increased level of absorption, when compared to the 
lead that has been ingested, usually, in larger sizes (digestive route), like lead chips in leaded paint.  
Despite the main important routes of human exposure are inhalation or ingestion, the dust and 
soil that contain lead can also be absorbed by the skin. However, it is unlikely to happen at the present, 
since lead gasoline has been banned, which was the main source of lead to be absorbed by the skin1,3,4,8. 
Moreover, only a little amount of the absorbed lead can pass through skin to the blood. Although, if 
hands are contaminated, lead can be ingested whilst eating, drinking, smoking, or applying cosmetics9.   
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Figure 1 - Environmental lead exposure cycle and its biological effects  
(extracted and adapted from Wani et.al, 201510) 
 
Occupational lead exposure can be defined as high levels of exposure to lead during a short 
period of time, targeting a specific group of subjects, usually at their working premises11. Environmental 
lead exposure5 involves a long-lasting exposure of large populations to lower levels of lead, of various 
sources, present in their living environment. Thus, the first can be considered a synonym of acute lead 
exposure, being of rare prevalence in developed countries where regulatory and safety procedures 
have been implemented, whereas the second, may represent a chronic contact to lead, being a public 
health issue in non-developed countries with high levels of lead emissions and the usage of old working 
methods in the industry and agriculture1,2,5,8.  
During an exposure, after entering the body and being absorbed, lead is primarily distributed 
among blood, mineralizing tissue, and soft tissues and organs (which include the liver, muscles, lungs, 
brain, kidneys spleen, and heart)1,12. Lead is not changed in the body and the metabolization of 
inorganic lead does not happen in the liver1. Approximately 99% of lead taken into the body in adult 
subjects will be excreted within a couple of weeks in the urine as the half-life of lead in adult human 
blood has been estimated as 28 days to 36 days. The fraction which is not absorbed will be excreted, 
via the bile, in the faeces1,4,5. Excretion of lead through sweat is of minor importance. However, only 
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about 32% of the lead taken into the body of an infant is excreted. Blood lead levels (BLL; µg/dL) and 
urine lead levels (not as usual) are measures used for diagnosis and treatment of lead toxicity13,14. A 
continuous exposure usually results in accumulation of lead in bone regions undergoing the most active 
calcification at the time of exposure. It is known that adults store about 94% of lead in bones and teeth 
whereas, in children, the amount is of around 73%1. It can stay there for decades, but can also re-enter 
the body circulation under certain circumstances (e.g., when a bone is broken, pregnancy and breast 
feeding or in osteoporosis cases in advancing age)1,10. In this condition, bone and kidney lead levels are 
usually used as greater measures of lead in the body15,16. Table 1 shows the differences between chronic 
and acute poisoning. 
The US Centre for Disease Control17, Prevention Centre and the World Health Organization 
(WHO)5,6,18 guidelines indicate that BBL´s ≥10 μg/dL are a cause for concern; however, lead may impair 
development and have harmful health effects even at lower levels19,20 as 5 μg/dL suggesting  that all 
lead levels may represent a danger to human health. 
Table 1 –Acute and chronic lead intoxication features.  
Main differences between acute and chronic exposure to lead regarding BBL’s, health effects and associated clinical 
symptoms. 
 Exposure Type of exposure 
Blood Lead 



















- Haemolytic anaemia 
- Muscle pain 
- Fatigue 
















- Mental retardation 





- Weight loss 
- Hyperactivity 
- Paralysis 
- Muscular weakness 
- Brain damage 
- Kidney damage 
- Frank anaemia 
- Hypertension 
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PREVALENCE AND EPIDEMIOLOGY OF LEAD TOXICITY 
Lead poisoning accounts for about 0.6% of the global burden of disease. The highest burden 
was estimated in low- and middle-income countries. Based on 2015 data, the Institute for Health 
Metrics and Evaluation (IHME) has estimated that lead exposure has accounted for 494 550 deaths and 
loss of 9.3 million disability-adjusted life years (DALYs) regarding the long-term effects on health. IHME 
also estimated that lead exposure accounted for 12.4% of the global burden of idiopathic 
developmental intellectual disability, 2.5% of the global burden of ischaemic heart disease and 2.4% of 
the global burden of stroke4. 
In USA, the Centre for Disease Control21, identified, in 2010, that approximately 24,000 children 
aged <6 years presented blood lead levels (BLLs) ≥10 µg/dL and approximately 243,000 children aged 
<6 years had BLLs ≥5 µg/dL. Regarding European countries, the prevalence of lead poisoning was 
addressed in the 2004 WHO Report22. Data from 24 studies and population surveys conducted between 
1996 and 2000 in children between 0 and 4 years allowed to divide European country into 3 categories:  
- EUR A: prevalence of 0.1%, comprising Croatia, the Czech Republic, Finland, France, Germany, 
Greece, Italy, Portugal, Spain, Sweden and the United Kingdom. 
- EUR B: prevalence of 2%, consisting of Armenia, Bulgaria, Poland, Turkey and Yugoslavia. 
- EUR C: prevalence of 17%, consisting of Russia and Hungary.  
In 2014, the European Environmental Agency (EEA) has performed a surveillance study on lead in 
the environmental air of EU countries. The results showed that ~97% of the surveillance stations 
detected levels of lead under 0.25 µg/m3 in the analysed air without stations sensing values of 0.5 
µg/m3. However, the area of extent of the exceedances of critical loads was more that 12% of the 
European Union ecosystem area23. 
The World Health Organization (WHO) and the International Programme on Chemical Safety have 
been concerned about the adverse health effects of environmental lead exposures for more than 35 
years. They convened working groups to evaluate human health risks and health-based guidance values 
of lead in water, workplace and air 4,5,8,24.  
Lead toxicity is one of the most common and well-recognized childhood diseases from 
environmental toxins and  children around the world, nowadays, are at risk of exposure to lead from 
multiple sources 4,24. Therefore, some countries developed robust programmes for monitoring levels of 
lead in blood and in the environment, as well as strong programmes for primary and secondary 
prevention of developmental lead toxicity. These countries have imposed bans on certain uses of lead, 
have set environmental standards and have arranged screening programmes4,5,8,24. In the other 
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countries where lead poisoning has not yet been recognized, there are no screening or surveillance 
programmes and, as a result, public health authorities have little or no knowledge of the existence of a 
childhood lead-poisoning problem. Thus, the contribution of lead poisoning to the global burden of 
disease and its effects on the global economy and human development are still underestimated1,5,7. 
MECHANISMS OF LEAD TOXICITY  
The mechanism of lead toxicity is not yet fully understood. Nevertheless, studies carried out 
reported various cellular, intracellular and molecular mechanisms behind toxicological manifestations 
resulting from lead exposure.  
Oxidative stress  
Oxidative stress is characterized as an imbalance between free radical production and the 
systems’ ability to detoxicate from reactive intermediates. This has been reported as the main 
mechanism of lead toxicity2,25,26.  
Two pathways are simultaneously activated at the onset of oxidative stress provoked by lead 
exposure. One is production of reactive oxygen species (ROS) occurs leading to a depletion of the 
antioxidant reserves headed by glutathione. Glutathione is the primary antioxidant in cells and it exists 
in both reduced (90%) and oxidized (10%) forms 25 which are interchangeable according to the cell 
environmental condition. The other pathway is related to lead’s ability to share electrons through 
covalent bonds between lead moiety and the sulfhydryl groups of the antioxidant enzymes which are 
lead main target. These enzymes may be inactivated by lead that binds to their sulfhydryl groups 
eliciting the synthesis of glutathione and forces the replacement of the enzyme zinc ions26. Lead has 
also the ability to inactivate other enzymes, which further reduce the glutathione levels26,27 such as 
super oxide dismutase and catalase. In addition, lead also promotes lipid peroxidation, haemoglobin 
oxidation, which directly causes haemolysis25,27,28. All these mechanisms make the cell extremely 
vulnerable to oxidative stress and may lead to cell death. Figure 2 schematically illustrates the oxidative 
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Figure 2 – Lead-induced oxidative stress and subsequent mechanisms leading to cell death 
(extracted and adapted from Flora, G., 2012 2) 
 
Ionic changes 
Lead also replaces various bivalent cations (calcium - Ca2+, magnesium - Mg2+, iron - Fe2+) and 
monovalent cations (such as sodium - Na+) by itself, which defines the ionic mechanisms of action of 
lead toxicity. These ionic changes may affect fundamental organic processes of the body29 impairing 
both intra and extra cellular processes such as intra and intercellular signalling, protein folding and 
maturation, cell adhesion, enzyme regulation, apoptosis, release of neurotransmitters and ionic 
transportation30. 
The ionic mechanisms of lead toxicity are the main contributor to lead neurological impairment 
as, after its replacement by calcium ions, lead has the ability to cross the blood-brain barrier and 
accumulate in astrocytes. Therefore, toxic effects of lead are more prominent in the developing nervous 
system, comprising immature astroglial cells that lack lead binding proteins. Lead effortlessly damages 
the immature glial cells and blocks the formation of myelin sheath, both factors involved in BBB 
development30–32. Even at picomolar concentration, lead replaces calcium, consequently affecting key 
neurotransmitters, like protein kinase C, which regulates long term neural excitation and memory 
storage. It also affects the concentration of sodium ions, which plays a major role in several vital 
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biological activities, like generation of action potentials in the excitatory tissues for cell to cell 
communication, retention of calcium by synaptosomes, uptake and regulation of uptake of 
neurotransmitters. Therefore, this interaction between lead and sodium extremely impairs the normal 
functioning of the sodium dependent processes 30–33. 
Activation of brain inflammatory pathways 
Microglia and astrocytes are the two main types of glial cells involved in the regulation of the 
immune response to pathological processes in the brain. Activation of both microglia and astrocytes 
result in neuroinflammation, associated with infection, autoimmunity, and pathogenesis of 
neurodegenerative diseases. Lead exposure leads to the insufficient supply of energy from astrocytes 
to neurons. Also, following lead exposure, astrocytes secrete various inflammatory cytokines, such as, 
TNF-α, IL-6, and IL-10 into surrounding tissues. These cytokines further mediate the immune response, 
including activation of microglia and macrophages, and induce other adverse reactions, which might 
eventually result in the destruction of BBB tight junctions. Overexpression of inflammatory stimuli in 
the brain neurovascular unit may start a response to clear antigenic material, leading to destruction 
and increase of BBB permeability together with neuronal damage34–37. In summary, the mechanisms 
related to microglia and astrocytic activation are schematically presented in Figure 3. 
 
Figure 3 - Neuroinflammation as lead induced toxicity mechanism  
Microglial and astroglial cells function in the generation of inflammatory cytokines and neuronal injury. Lead may contact 
and trigger microglial and astrocytic activation, enhancing inflammatory cytokines and their response, increasing ROS and 
oxidative stress, resulting in BBB dysfunction, long‑term potentiation inhibition and inflammatory neuronal injury.  
(extracted from Liu, J., 2015 34) 
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LEAD EFFECTS ON HUMAN HEALTH  
Lead toxicity has the potential to cause irreversible health effects interfering with a wide number 
of body functions. 
Lead and the cardiovascular system 
Population studies have demonstrated that lead toxicology is associated with cardiovascular 
disease38–41. Studies from the early 1920s showed that long-term and high dose lead exposure 
correlates with an increased incidence of hypertension and brain stroke. More recently, several 
epidemiological studies evidenced that increased lead absorption, even at relatively low levels, is also 
consequent with significant elevation in blood pressure across general populations with no 
occupational exposure to lead 40,42. Other studies in human subjects and in experimental animal models 
also identified a dose-dependent relationship between lead exposure and higher blood pressure 40,42. 
Beyond hypertension, few studies in general populations have identified a positive association between 
exposure to lead and clinical cardiovascular events (mortality due to cardiovascular disease, coronary 
heart disease and stroke and peripheral arterial disease), some of them observed at blood lead levels 
≤5 μg/dL. 40,43. 
Molecular studies have shown that chronic lead exposure promotes oxidative stress, limits nitric 
oxide availability impairing nitric oxide signalling, increases adrenergic activity, raises vasoconstrictor 
prostaglandins lowering the vasodilator ones, promotes inflammation, increases endothelin 
production, alters renin-angiotensin signalling, disturbs calcium signalling in smooth muscle vessels, 
diminishes endothelium-dependent vessels relaxation and modifies the vascular response to vasoactive 
agonists causing HTN 25,42,44. Additionally, it was shown that lead causes endothelial injury, prevents 
endothelial repair, inhibits angiogenesis, supresses proteoglycan production, stimulates vascular 
smooth muscle cell proliferation and phenotypic transformation, reduces plasminogen activator and 
raises plasminogen activator inhibitor-1 production.  All these actions, and others not yet known, 
caused by lead exposure, are the key mechanisms that cause HTN and promote atherosclerosis, 
thrombosis, arteriosclerosis and cardiovascular disease40,42,44.  
Lead and the autonomic nervous system 
Autonomic function is not known to be primarily affected by chronic lead exposure. However, 
the parasympathetic nervous system has been described as being affected by Pb-poisoning causing 
autonomic dysfunction45. Additionally, it was shown that lead increases the co-inhibition of sympathetic 
and parasympathetic activation during psychological stress and, also, reduces the baroreflex sensitivity, 
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vagal parasympathetic tone and increases sympathetic activity by mechanisms that include impairment 
of dopamine and acetylcholine transmission and oxidative stress43. 
Baroreflex hyposensitivity, sympathetic overexcitation and decreased parasympathetic tone are 
associated to several pathologies, such as, hypertension, acute cardiac ischemia or even heart failure. 
The mechanisms underlying those pathological effects have not yet been fully clarified, but it is thought, 
that there is an initial protective reaction that turns into deleterious sympathoexcitation with the 
passing time45. Studies have shown that chronic lead toxicity produces an increase in sympathetic 
activity that underlies alterations, namely high blood pressure, tachypnoea, decrease in baroreflex 
function and increased chemoreflex sensitivity 43. Until last year, there were no evidences of 
chemoreflex function changes, but a recent work has shown that there is an increase in chemoreceptor 
reflex sensitivity, suggesting that chemoreceptor reflex could be involved in oxygen homeostasis 
maintenance in a similar way to hypertensive patients that exhibit an augmented ventilatory response 
to hypoxia and an increased sympathetic nerve activity43,45. 
Apparently, lead toxicity interferes with brainstem cardiorespiratory network function which, in 
turn, could account for the higher sympathetic tone5,43,45. Data shown in a recent study strongly 
indicates that both carotid body reflex, a protective sympathoexcitatory reflex, and the central 
autonomic network are involved in the augmented chemoreflex response and, this involvement, may 
contribute to the increased baseline sympathetic activity that was observed45. The mechanisms 
underlying those changes are yet unknown, but it has been hypothesised that those linking the 
hypothalamus with lower brainstem nuclei, especially, the PVN-NTS axis may be involved in the 
observed functional changes46. In addition to those mechanisms, the baroreflex impairment that has 
been described in lead poisoning and in other pathologies is one of the major consequences of 
persistent increase of sympathetic tone and arterial blood pressure 43,45,46. 
The most recent studies (from 2017) of low-level and sub-chronic lead exposure in rodents 20,47 
have shown that arterial hypertension in animals was accompanied by an increase in sympathetic tone 
and decrease in vagal tone, baroreflex impairment without changes on cardiopulmonary reflex.  The 
changes went together with an increase in the renin-angiotensin system mediated by the AT1receptor 
activation and decrease in nitric oxide (NO) bioavailability. As a compensatory mechanism of the 
changes found in the sympathetic tone, a downregulation of β1- adrenoceptors in the heart was 
described. These studies have shown that levels of lead below BLL cut-off for lead toxicity promote 
alterations in autonomic and cardiovascular system and should be considered as a risk factor for 
cardiovascular disease. 
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Neurological effects of lead  
Brain is considered to be the most sensitive organ to lead exposure. Research in the past decades 
for characterizing lead toxicology has shown lead as a potent neurotoxicant, especially during nervous 
system development37,48. Various deleterious effects have been described, including cognitive 
impairment49–52 in children that persists in adults, even with low BBLs (<5µg/dL). Also, a positive 
correlation between lead exposure and the increase of neuropsychiatric disorders, such as attention 
deficit hyperactivity disorder and antisocial behaviour has been described. Other researchers reported 
that violent crimes in adulthood are correlated to lead exposure in prenatal and early childhood 
periods19,53,54. Due to the ability of lead to bypass BBB by replacing calcium ions and being taken up by 
calcium-ATPase pumps, lead can interfere with synapse formation (in particularly in children), 
production of neurotransmitters and organization of ion channels30.  
Novel findings in this area of research also include advances in understanding the mechanisms 
and cellular specificity for Pb. Studies have shown that stress alters Pb effects that are mediated by 
modifications in glucocorticoids, a brain mesocorticolimbic dopamine system which is involved in 
several pathologies. Lead-induced cognitive impairments have been studied in cellular models of 
learning and memory by examining the long-term potentiation in rodent hippocampus by increasing 
threshold, decreasing magnitude and shortening retention times of synaptic plasticity37,50. Hippocampal 
modifications may be the main reason for lead interference with learning, particularly in children, at 
molecular and morphofunctional levels of neurons and glial cells52,55,56. Lead exposure also impairs 
structural plasticity in adult neurogenesis in the hippocampus, causing perturbations in synaptic 
plasticity by acting on glutamate release, NMDA receptor function and structural plasticity and thus, 
contributing to learning impairments 30,54,57 .  
In vitro models also evidenced that lead binds to 78-kDa molecular chaperone glucose-regulated 
protein (GRP78), inducing its aggregation and, consequently, blocking IL-6 secretion in astroglial cells. 
In the long term, chaperone deficiency could trigger protein conformational diseases, such as, 
Alzheimer’s Disease (AD) and Parkinson’s Disease (PD)37,54,58. These results are in contradiction with 
others from studies on the mechanisms of lead toxic effects where IL6 levels are increased. 
Furthermore, lead exposure in early life has been implicated in subsequent progression of 
amyloidogenesis in elder rodents. This exposure resulted in an increase in proteins associated with AD 
pathology, beta-amyloid precursor protein (β-APP), and beta-amyloid (Aβ)59. 
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PREVENTION, TREATMENT AND REDUCTION OF LEAD TOXICITY 
The first step in treating lead poisoning is to remove the source of the contamination. For 
children and adults with relatively low lead levels, simply avoiding exposure to lead might be enough to 
reduce blood lead levels. However, when levels are high, oral therapy with chelating agents 
(dimercaprol and succimer60) is proposed to promote lead urinary excretion. This therapeutic algorithm 
is essentially recommended for children with circulating levels ≥45 µg/dL or adults with symptoms of 
lead poisoning. The use of injectable EDTA as a chelating agent is particularly used in adults with serious 
lead levels (≥45 µg/dL) and for children who do not tolerate oral chelating agents. Antioxidants have 
been also described as promising agents for lead poisoning treatment and removing its related 
compounds mainly through nanoencapsulation2. 
Although, the availability of various treatments, they only ameliorate the deleterious effects 
already caused by lead poisoning. Considering the toxic effects of lead, preventive measures are 
preferred over the treatment regimens as, once lead enters the body, it is almost impossible its 
complete removal and the reversal of its damaging effects. A preliminary preventive approach towards 
lead toxicity is defined as a three-way plan which includes individual intervention, preventive medicine 
strategy and public health strategy61. To each individual at risk it is recommended to frequently wash 
their hands, to discourage putting contaminated hands in the mouth and to increase the intake of 
calcium and iron, other mineral elements, flavonoids and vitamins 1,2,10,62,63. Preventive medicine 
strategy aims mainly at screening children whom are at risk of lead exposure61. Various preventive 
strategies have been suggested by the public health services for controlling lead4,18,64. The most 
important of them include the prohibition of setting up industries dealing with lead close to habitable 
areas and the complete banning of lead usage whenever appropriate like as happened with the leaded 
gasoline and leaded paint banning. 
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TRANSLATION FROM ANIMAL TO HUMAN STUDIES 
Choosing the animal specie 
Various population studies have been carried out since lead has been a concern for the human 
health. However, due to the vast variability of health effects that has been reported, mainly because of 
the diversity of human exposures, environmental confounders and genetic backgrounds of the 
populations, animal and molecular studies were performed over the years to study specific health 
effects that were observed in the human populations and mechanisms underlying those effects.  
Studies in rodents and nonhuman primates have demonstrated the same cardiovascular8,42,45, 
haematological41,65,66, neurodevelopmental31,48,55,58,67–69, and renal lead adverse effects66,70 , that have 
been observed in humans, providing insights into possible mechanisms underlying the health changes 
that low-level lead exposure provokes. These studies also provided the support for the concept of blood 
lead concentration as a metric of internal dose for use in dose-response assessments in humans.  
Rodents are the most used animals in different types of research. Lead exposure health effects 
have been vastly studied in rodents as well33,65,68,71–74. However, comparing rats and mice, rats are a 
better animal model comparing to mice for numerous reasons. First, the rat is genetically, 
physiologically and morphologically closer to humans than mice75,76. Its large body and brain size 
facilitates drug administration, in vivo electrophysiology, as well as neurosurgical/stereotaxic and 
neuroimaging approaches. Second, the mouse represents a less complex behavioural repertoire and 
much less flexibility in dealing with novel situations. Moreover, the rat appears to be more 
advantageous in its use in neurobehavioral research, presenting a higher level of behavioural 
functioning complexity, when compared to mice. These behavioural variations may be accounted since 
rats, like humans, and opposed to mice, have a post-natal brain development that might result in an 
extra wide variety of synapses76. Therefore, the rat, as an animal model of disease and toxicology, 
including low-level lead exposure animal models allow a more state-of-the-art characterization of 





Liana Shvachiy   |   13 
 
Experimental protocols to mimic human chronic low-level lead exposure  
Due to the importance of animal models in toxicological studies, chronic low-level lead 
exposure animal models have been developed and used for over 40 years. In 1976, Kostas and her 
collegues77 exposed Long-Evans dams and pups to different concentrations of lead (5%; 0,5%; 0,05% - 
by weight), mixing lead acetate in the chow that was fed to animals. At 21 days of age of the pups, the 
concentration was reduced (25, 2.5 and 0.25 ppm). At 45 days after birth of pups, animals underwent 
behavioural evaluation for memory and locomotor activity assessment. This type of lead exposure is 
representative of an exposure to lead by ingestion in children from foetal period and until early ages of 
life. In the same year, other authors78 exposed Sprague-Dawley pregnant female rats to high lead 
acetate solution and low lead acetate solution diluted in water. The pups, after birth, underwent the 
same exposure until 30 days of age. After exposure, animals were tested with open field test for 
locomotor and exploratory activities. The authors of both studies, although using different routes of 
lead exposure with different concentrations, only assessed the general behavioural alterations in the 
animals, without performing other analysis, for a more complete evaluation of toxicological effects of 
lead. 
In 1980, Grant. and collegues72 also performed a study in Sprague-Dawley animals. Females 
were exposed to increasing concentrations of lead diluted in water and divided in two groups (Group A 
- 0, 0.5, 5.0, 50, and 250 ppm and Group B - 0, 5, 25, and 50 ppm) 6-7 weeks before mating with non-
exposed males. Pups were exposed to the same lead solution and were evaluated at different 
timepoints from day 1 after birth until 9 months. General health observations, physical development 
landmarks, pre and post weaning behavioural evaluations were performed in this study. These authors 
performed a more complex study than the previous ones, testing different physiological and 
behavioural parameters and various concentrations of lead exposure through a long period of time. 
Cory-Slechta, in 198579, exposed Long-Evans hooded rats to 25 ppm lead acetate dissolved in distilled 
water from 20 days after birth until 50 days. At 50 days of age, authors performed behavioural 
evaluation using operant chambers. This was a simple study with a short exposure to low-levels of lead 
in animals during development. 
Boscolo and Carmingani , in 198844, performed a more complex study in Sprague-Dawley rats 
that received 0, 15, 30, and 60 ug/mL of lead acetate dissolved in deionized drinking water for 18 
months. Authors evaluated various physiological parameters in anaesthetized animals, assessing 
cardiac inotropism, pressor, inotropic and chronotropic responses. Blood and organ lead levels were 
determined by atomic absorption spectrophotometry. Some years later, in 1993, Altmann and 
colleagues56 completed a study in Wistar animals. Female Wistar rats were fed diets containing 0 and 
750 ppm lead acetate, for 50 days prior to mating, during gestational period and until 16 days after 
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birth. Animals were tested for active avoidance learning and LTP was measured in hippocampal slices 
and brain and blood lead levels were determined. Such a study is an example of a complex 
neurotoxicological assessment of lead exposure which includes behavioural and electrophysiological 
evaluation, comparing the effects to lead levels. 
In 1996, Bielarczyk80 published a new animal model of chronic low level lead exposure, in which 
the authors exposed pregnant Sprague-Dawley animals (7 days before parturition) with 0.2% lead 
acetate solution. After birth, pups were exposed until weaning at 28 weeks of age, after which animals 
were maintained at normal drinking diet. Unilateral superior cervical ganglionectomy and partial 
bilateral transection of fimbria-fornix were performed and cholinacetyltransferase and tyrosine 
hydroxylase activities and blood lead levels were assessed. In the same year, Lasley and Gilbert81 
exposed Long-Evans dams at 14-15 days of gestation to 0.2% lead solution and the pups from day 1 to 
135 after birth. Blood lead levels were determined, intracerebral dialysis, chromatography for GABA 
and glutamate quantification and electrophysiological evaluations were performed. Zawia and Harry71 
in the same year, used Long-Evans animals and exposed pups to 0.2% lead solution from postnatal day 
1 until 20 days through dams. Total RNA isolation and estimation, Northern analysis and specific mRNA 
quantification were performed. All these authors established the developmental lead exposure animal 
models, however, Bielarczyk80  characterized lead health effects during foetal and developmental 
periods.   
One year after, in 1997, three studies were published. Kuhlmann57 exposed male Long-Evans 
rats animals to a pelleted Pb-containing diet (750ppm) during different stages of development for 
reference memory (Morris Water Maze) and blood lead levels assessment at 100 days of age. Jett et 
al.82 published a different kind of lead exposure protocol. Ten days prior to breeding and through 
gestation and lactation, female Long-Evans rats were fed diets containing 250 ppm of Pb acetate. Pups 
were exposed from day 1 until day 91. Behavioural evaluation with Morris Water Maze and Pb levels in 
the hippocampus were assessed in this study. These studies are complementary, being published by 
the same research group, evaluating the memory deficits in an animal model that mimics lead exposure 
through contaminated food ingestion by pregnant females and their children. However, only the 
behavioural alterations were considered on both these studies, without any neuropathological 
evaluations. The third study was published by Bourjeily and Suszkiw83. These authors exposed timed-
pregnant Sprague-Dawley rats with 0.2% lead acetate solution diluted in water from gestational day 16 
until weaning pups at post-natal day 21 (P21). Rats (females’ pups) were sacrificed at P1, P7, P21, P81, 
P112 and P200 for biochemical and morphological measurements. This study presents a similar lead 
exposure animal model to that described before by Bielarczyk80 but without developmental post-
weaning exposure and with an evaluation of the animals made after a long non-exposure period (8, 12 
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and 24 weeks). Even though this is a complex study, only molecular changes of lead exposure were 
considered, without describing any physiological or behavioural changes. The same protocol of 
exposure was published some years after (in 2007) by Han et al84, to study the protective effects of 
ascorbic acid in lead toxicity. This type of studies is crucial as an attempt of finding a treatment or 
prevention of lead toxicity in humans by performing animal experimentation. 
Moreira85 and others published, in 2001, a wide-ranging behavioural study on lead-exposed 
animals. For that, researchers exposed pregnant Wistar rats with 500pm Pb acetate solution during 
pregnancy and lactation. Pups, at 23 and 70 days of age, were assessed by elevated plus maze and open 
field tests, holeboard and shuttle-avoidance tasks, social interaction test and rotarod for a broad 
behavioural characterization upon lead exposure during development. Also, Pb levels in brain and blood 
were determined in both dams and pups. Such a study is very important for a wide characterization of 
an animal model, however, only the behavioural changes during development of the brain in foetal 
period and during lactation were considered, without any molecular or physiological evaluation. In 
2003, Yang86 developed, using Wistar rats, a gestational lead exposure animal model, without taking 
into account the developmental phase and evaluated only the cognitive impairment induced by lead 
exposure by Morris Water Maze test.  
In 2005, Virgolini87 and colleagues published a long-term study of chronic low-level lead 
exposure (50 and 500ppm drinking lead solution), starting at day 21 after birth and until 9 months of 
age of male Long-Evans rats. Animals were assessed for behavioural changes by fixed interval 
performance test, stress challenges and locomotor activity chambers and catecholamine, 
corticosterone and glucocorticoid receptor levels were determined, as well as blood lead levels, 
through lifetime. This study is an example of an overtime research for toxicological lead effects upon 
behaviour of the animals and, therefore important for results translation humans, although not taking 
into account the foetal period of exposure and only evaluating the changes in male animals. Also, the 
molecular changes that underlie the behavioural changes observed were considered and assessed for 
a wider examination of lead effects. 
A group of scientists from Poland, led by Struzynska, in 200788 described a completely new way 
of lead exposure in animals. Wistar rats of both sexes were injected daily with lead acetate (15 mg/kg, 
ip) for 2 weeks starting at day 15 after birth. Animals were sacrificed 24 hours after the last injection 
and brains removed for a broad inflammatory study of glial and neuronal cells. Blood and brain lead 
levels were also estimated. Although this a very complex study of mechanisms of lead toxicity in the 
brain, the type of exposure to lead is not well translated to human environmental exposure. Even 
though, this type of studies is important to characterize the molecular mechanisms underlying lead 
neurotoxicity. Other studies with injectional lead exposure animal model were published after the 
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previously described. In 2014, Silveira et al89 published a study in which authors exposed male rats to 
lead acetate (first dose 4mg/100g, subsequent doses 0.05mg/100g,im) for 30 days, in animals that 
weighted between 250–300g. Vascular reactivity experiments in thoracic aortas were performed, 
indirect systolic blood pressure was measured weekly using tail-cuff plethysmography and molecular 
studies for oxidative stress assessment, as well as blood lead levels were determined. Another study, 
of 201690, was performed in two months old female Wistar rats that were exposed to lead acetate 0.5 
mg/kg by intraperitoneal injection for 60 days. The authors performed some histopathological and 
immunohistochemistry analysis for lead effects assessment on molecular level. Also, in 2017, Simões47 
and collaborators published a very broad study of physiological and autonomic dysfunctions in Wistar 
rats, exposing adult male Wistar rats to lead acetate by intramuscular injection (first dose of 4 µg/100 
g body weight and subsequent doses of 0.05 µg/100 g/day for 30 days). Haemodynamic recordings in 
conscious rats were performed for BP changes assessment and systolic arterial pressure and pulse 
interval variability calculated for autonomic evaluation using Fast Fourier Transform (by LF, HF and 
LF/HF calculations), baroreceptor and Bezold–Jarisch Cardiopulmonary Reflexes were also determined. 
This is a very wide-raging study of cardiorespiratory and autonomic changes in animal model that could 
be translated to children that are exposed to lead in early stages of life, however, the type of exposure 
that have been chosen by the authors is not the type of exposure that happens in the normal conditions 
with humans.  
Some studies have been focused in the relationship of lead exposure and neurodegenerative 
diseases, such as Alzheimer’s disease. New animal models have been developed to investigate the 
association. Bihaqi69et al in 2014, described the first double lead exposure animal model, exposing 
C57BL/6 mice to 0.2% Pb acetate through drinking water from day 1 to 20 after birth and between 9 
and 9 months of age. Brains were removed in different timepoints of the study (post-natal days 20, 180, 
270, 540, and 700). Behavioural assessments were performed by Morris Water Maze and elevated plus 
maze, western blotting and real-time PCR to trace Alzheimer’s biomarkers. The same group of 
researchers, published another study in 201691 in which only the developmental lead exposure profile 
was evaluated (C57BL/6 mice exposed to 0.2% Pb-acetate from PND 1 to PND 20 through the drinking 
water of the dam) with similar testing protocol of the previous study. Both these studies, and others 
that have been performed, have shown a strong relationship between lead exposure in early stages of 
life and the development of Alzheimer’s and other neurodegenerative diseases in elder stages of life, 
although, using a simpler animal species for evaluation. 
In the most recent years, other studies with animal models have been developed. Sobin et al68 
published, in 2017, their work that was performed in female and male C57BL/6J mice exposed to low 
(30ppm) and high (430ppm) lead acetate solution from day 0 to day 28 after birth. Behavioural 
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evaluation by OIP task (object-in place) for spatial and visual object memory retrieval in preadolescence 
mice. No molecular or physiological assessments were performed. Although, the study mimics the 
human exposure in the early stages of life, no broad evaluation of the lead effects has been performed. 
Another study was performed in 2017 by Toscano and collaborators20, focused in the physiological 
alterations provoked by lead, in which two months old male Wistar rats were exposed to lead acetate 
(100ppm) for 30 days. Systolic blood pressure (SBP) was assessed weekly by tail plethysmography and, 
after 30 days of lead exposure, haemodynamic measurements were taken (sBP, dBP and HR), blood 
pressure reactivity, baroreflex stimulations were performed and heart was withdrawn for western blot 
analysis of β1 adrenergic receptor expression. This is a more complex study with a broader evaluation 
of lead exposure effects during developmental stages, in which, not only the physiological parameters 
have been assessed, but also, the neural regulation system dysfunction that underlies the physiological 
changes evaluated and described. 
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2  AIM OF THE WORK 
Lead exposure can be highly variable in both intensity and frequency inducing, during 
developmental stages and through lifetime, adverse health effects including behavioural changes, 
cognitive impairment, tachypnoea, hypertension and autonomic dysfunction. Most of these adverse 
effects have been described in the course of a continuous chronic exposure to lead in both humans and 
animals. In fact, various animal models have been described for continuous low-level lead exposure and 
health effects assessed. Yet, there are situations eg, migrations, implementation of school exchange 
programs and/or residential change, where intermittent lead exposure occurs and may leading to 
functional damage. However, the available studies in human subjects and standardized exposure 
protocols mimicking human intermittent exposure to lead are scarce.  
Therefore, the overall purpose of this Master thesis is to evaluate lead effects on mammal’s 
physiology along different profiles of lead exposure, including a new protocol of intermittent low-level 
lead exposure.  
 
For that, 
- three different protocols of lead exposure were developed; 
- leading functional parameters, critical for cardio-respiratory and autonomic homeostasis, were 
characterized; 
- behavioural changes and cognitive impairment produced by lead exposure were assessed; 
- morphofunctional parameters as neuronal degeneration, gliosis and synaptic alterations in the 
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3 MATERIALS AND METHODS 
3.1 ETHICS STATEMENT 
All described procedures were carried out in agreement with the European Community 
legislation on animal experimentation (Directive 2010/63/ EU) and were approved by the Ethical 
Committee of the Academic Medical Center of Lisbon (CAML).  
3.2 DEVELOPMENT OF LEAD EXPOSURE PROTOCOLS  
By taking into account that ingestion is one of the three main intake routes for body lead 
absorption, animal models of lead poisoning were developed as described previously 16,45. Briefly, seven 
days pregnant Wistar rats (n=8; Charles River Laboratories, France) were divided into Pb-treated and 
control groups. In Pb-treated group, the tap drinking water was replaced by 0.2% (p/v) lead acetate (II) 
solution dissolved in deionized water (Acros Organics, New Jersey, USA). After weaning at 21 days, rat 
pups of both sexes were divided into two groups following the previous exposure: Pb-exposed pups 
(Pb) and tap water for control pups (Ctl-rats).  
These two groups were themselves sub-divided into the following ones (Figure 4): 
• Long-term Exposure (PbP)   Wistar rats (n=30) of both sexes were exposed to lead 
permanently and evaluated at 12, 20 and 28 weeks of age;  
• Short-term Exposure (PbS)  Wistar rats (n=30), of both sexes, exposed to lead solution until 
12 weeks of age without any adult lead exposure, evaluated at 12, 20 and 28 weeks of age;  
• Intermittent Exposure (PbI)  Wistar rats (n=30), of both sexes, exposed to intermittent lead 
intake (two periods of exposure): until 12 weeks of age and between 20 to 28 weeks. 
Animals underwent a period of lead abstinence for 8 weeks, between 12 and 20 weeks of 
age and were evaluated at 12, 20 and 28 weeks of age; 
• Without exposure to Pb (Control - CTL) Wistar healthy rats (n=30), of both sexes, not 
exposed to lead were evaluated at three different time-points: 12 week, 20 weeks and 28 
weeks.  
All animals were subjected to the same experimental protocol at three distinct time-points (T= 12, 
20 and 28 weeks of age) for a broad functional and morphological characterization of lead exposure 
profiles. 
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Figure 4 - Timeline of the study, discriminating the development of different low-level lead exposure protocols (PbP, PbI and 
PbS) and the matching control (Ctl).  
Numbers represent different evaluations performed at relevant time-points of the study: 1 - Behavioural tests and 
Functional evaluation; 2 - Behavioural tests, Functional evaluation and Immunofluorescence studies; 3 - Behavioural tests, 
Functional evaluation and Immunofluorescence studies. 
 
All rats were housed in the animal facility of the Faculty of Medicine of the University of Lisbon, 
in a maximum number of 4 animals per cage and divided by sexes (after weaning, at 21 days of age), 
with controlled temperature (22 ± 1°C) and humidity (50 ± 5%) and synchronized for a 12/12h light/dark 
cycle (lights on between 7 am and 7 pm). Food (Mucedola, Italy) and tap water (Epal, Portugal) were 
provided ad libitum. All procedures (functional and behavioural evaluation) were performed during the 
light period of the day. 
3.3 BEHAVIOURAL TESTING PROCEDURES 
Two weeks before functional evaluation, animals underwent a set of standard behavioural tests 
to access: I) anxiety and stress levels92 (Elevated Plus Maze test); II) spontaneous locomotor activity and 
exploratory behaviour93 (Open Field Test); III) spatial working memory94 (Y-Maze test); and, IV) episodic 
long-term memory95 (Novel Object Recognition test).  
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At the experimental days, animals were taken into the behaviour testing room, for at least, 1h 
prior to the start of the testing session. All behavioural studies were performed between 9am and 6pm, 
in a quiet room with dim light and all animals underwent a prior handling period for testing room and 
researcher habituation96. All behaviour apparatus used were cleaned with 70% ethanol between 
animals, so that any residual smell of the disinfectant was experienced equally by every animal. After 
placing the animal in the behavioural apparatus, the investigator immediately left the room, to avoid 
introducing an unintentional bias into the study or serving as a cue for the animal. All experiments were 
video-recorded by an UV camera (Chacon, Belgium) and all videos were posteriorly analysed by ANY-
maze© software (Stoelting Co, Ireland). 
I. Elevated Plus-Maze  
The elevated plus-maze (EPM) is one of the most used tests of anxiety behavior evaluation in 
rodents92,97. The apparatus consists in an elevated maze with four arms (two open arms – 50 x 10cm - 
perpendicular to two enclosed arms 50 x 10 x 30cm height) that form a plus shape, elevated 50cm from 
de ground (Figure 5).  
 
Figure 5 - Elevated plus test apparatus. 
The apparatus consists in an elevated maze with four arms (two open arms – 50 x 10cm - perpendicular to two enclosed 
arms 50 x 10 x 30cm) that form a plus shape, elevated 50cm from de ground.  
Each animal was left at the centre of the maze to freely explore the maze during 5 minutes 
without prior habituation to the maze. Usually, a trial of 5 min is sufficient to capture the critical 
components of anxiety behaviour in animals98.  
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The parameters evaluated from the EPM test were: the number of entries in each zone (all four 
paws on open or enclosed arms); the percentage of time spent in open and closed arms using the 
following ratio: [time spent in open or closed arms/total time] x 100. Normal exploratory 
behavior in rodents is in favor of the closed arms 99; thus, animal exposure to a novel maze area evokes 
an avoidance conflict which is stronger in open arm compared to the enclosed one, being a lower ratio 
an indication of anxiety92,100. 
II. Open Field Exploration test 
The Open Field Test (OFT) provides a unique opportunity to systematically assess novel 
environment exploration, general locomotor activity, and allows an initial screening for anxiety-related 
behaviour in rodents,101. This apparatus consists in a square black box (measures of 67 x 67 x 57cm 
height) “virtually” divided in three concentric squares: 1- peripheral zone (near the walls), 2- 
intermediate zone and 3- centre, as shown, in Figure 6.  
 
Figure 6 - Open field test apparatus.  
The OFT apparatus consists in a square black box (measures of 67 x 67 x 57cm height) with three virtual zones 
discrimination: 1. Periphery zone; 2. Intermediate zone; 3. Central zone.  
The locomotor behaviour has been tested without previous habituation to the box. Usually, a 
5-min test session is sufficient to evaluate the general exploratory locomotion. It is known that rats 
typically spend an appreciably greater amount of time exploring the periphery of the arena, usually in 
contact with the walls (i.e., thigmotaxis)102–104, than in the unprotected centre area105.  
The parameters evaluated during this test were: the percentage of time spent exploring the 
centre, the total amount of entering times into the three virtual zones, the total travelled distance and 
the average velocity of the animal during the test93. The total amount of entries in the virtual zones and 
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the presence time in the central zone are measures of exploratory behaviour and anxiety. A high 
frequency/duration of these behaviours indicates high exploratory behaviour and low anxiety levels, 
and, in the contrary, a low frequency/duration of these behaviours is indicative of poor exploration and 
high anxiety levels93. Total travelled distance of the animal and average velocity are measures of the 
general locomotor activity85,93,106. High values of both these parameters are indicative of hyperactivity 
behaviour of animals, and, in the contrary, decreased values of these parameters indicate a locomotor 
impairment93,107. 
III. Y-Maze 
Y-Maze Spontaneous Alternation94 is a behavioural test taking advantage of the willingness of 
rodents to explore new environments92,101,108. The Spontaneous Alternation Behaviour measured in this 
test mirrors the process of spatial working memory - hippocampal dependent process94. It is a simple 
memory test, reason why it has been widely used by behaviour researchers and already used for lead 
neurotoxicity studies49. 
The apparatus for Y-Maze test consists of an Y-shaped labyrinth with a black interior, with three 
identical arms at angles of 120 ° (arm dimensions of 35cm length x 10cm width x 20cm height) was 
used. Visual hints were placed on the walls to mark a previous visit. (Figure 7). The detailed protocol 
was described elsewhere49. Briefly, each rat was placed at the end of one arm (the chosen arm) and 
allowed to move freely through the maze during 8 min, without prior habituation.  
 
Figure 7 - Y-Maze apparatus. 
 A wooden Y-shaped labyrinth, with the interior in black, with three identical arms at an angle of 120 ° of the other.  
The arm dimensions: 35cm x 10cm x 20cm. 
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The series of arm entries were calculated. An entry occurred when all four limbs were within 
the arm and an alternation was defined as entries in all three arms on consecutive occasions. The 
number of maximum possible alternations for each animal was therefore the total number of arm 
entries minus two. The percentage of spontaneous alternation behaviour (SAB) was calculated as 
following: [actual alternations/maximum alternations] x 100. In addition, and for each animal, 
the total number of arm entries was used as a measure of exploratory activity 94. 
 
IV. Novel Object Recognition Test 
The Novel Object Recognition (NOR) Test is very useful to evaluate different types of memory 
through manipulation of the retention interval (RI) that resembles the amount of time that animals 
must retain the information of the sample objects presented during the training phase, before the test 
phase.95 Since the aim of this test was to study the long-term memory changes of the animals, in our 
protocol, a retention interval of 24h was chosen95.  
To perform this test, the open field (OFT) arena (square black box with measures of 67 x 67 x 
57cm height) was used. The objects used, were transparent and brown glass shapes proportional to 
the animal size. There were various examples of every object (n=2), and they were randomized and 
used interchangeably between trials. The role of the object, namely sample or novel, was randomized 
between object types. Also, their position relatively to the other object was permuted with the aim of 
using every object as a familiarity or novelty. The object position was frequently changed so that the 
object exploration of the animal was independent of that specific object preference by the animal95,109. 
The objects were attached to the bottom of the arena with a round piece of Velcro that could not be 
seen or touched by the animals. The objects were placed in symmetric and opposed corners of the 
arena95.  
The testing protocol, schematically described in Figure 8, consists of three phases: habituation, 
training and the testing phase. In the habituation phase (3 consecutive days), each animal could explore 
freely the open field (OFT) arena for 15 min in the absence of objects. In the initial 5 min of the first day 
of habituation, animal behaviour was quantified as a measure of locomotor activity (OFT) throughout 
the ANY-maze® software. During the training phase, in the fourth day, the animal was presented with 
the two objects to-be-familiarized, named as sample objects (S and S’ objects) for 5 min. Following 
sample-objects exposure, the animal was put back to the home cage for 24h. During the test phase, the 
animal was exposed to two objects: one previously experienced (sample object -S) and a novel object 
(N), for 5 min 95. 
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Between every trial, the arena and the objects were carefully cleaned with a 70% ethanol 
solution to erase any olfactory clues. Training and testing days were recorded and analysed by 3-point 
analysis (head, torso and tail of the animal) using ANY-maze® software, and only the data from the head 
point analysis was relevant for exploration of the objects. Exploratory behaviour was quantified as the 
amount of time animals spent around each object in both, training and testing phases. The number of 
approaches that included sniffing the object, rearing towards the object or touching the object, were 
counted. Sitting backwards to the object or crossing in front of the object without pointing the snout in 
the object direction was not considered as exploration95. Exploration was quantified as following:  
ET (%)= [time exploring the object/overall exploring time] x 100.  
 
 
Figure 8 - Novel object recognition test schematic representation.  
 
Novelty index was calculated from the data obtained in the NOR testing day, as:                          
[ET% Novel – ET% Sample] / [ET% Novel + ET% Sample]. This index ranges from -1, to 1, 
where negative values to 0 represent absence of discrimination between novel and familiar objects, 
i.e. more time exploring sample object, equal time exploring both objects, and 1 corresponds to 
exploration of the novel object only. 109 
  
Materials and Methods 
26   |   Liana Shvachiy 
 
3.4 FUNCTIONAL EVALUATION 
Metabolic evaluation 
Animals were housed in a metabolic cage for 24h for food, water intake and urine and faeces 
production quantification. Animals were weighted before and after being placed in the metabolic cage.  
Cardiorespiratory and autonomic evaluation 
Anaesthesia, surgical and experimental protocols 
Wistar rats, both sexes, aged > 12weeks, were anesthetized with sodium pentobarbital (60 
mg/kg, ip). The levels of anaesthesia were maintained, when necessary, with a 20% solution (v/v) of the 
same anaesthetic, after testing the withdrawal reflex. The trachea was cannulated below the larynx for 
recording of the tracheal pressure and artificial ventilation (if necessary) with O2-enriched air through 
a positive pressure ventilator. Femoral artery and vein were cannulated for blood pressure monitoring 
and injection of saline and drugs, respectively. Rectal temperature was maintained between 37.5-39ºC 
through a homoeothermic blanket connected to a rectal probe (Harvard Apparatus). The 
electrocardiogram (ECG) was recorded from subcutaneous electrodes placed into three of four limbs; 
heart rate has been derived from the ECG recording (Neurolog, Digitimer). The right carotid artery 
bifurcation was identified, and the tip of a catheter was placed within the right carotid sinus by 
retrograde cannulation of the external carotid artery. Carotid body receptors were stimulated by the 
injection of lobeline45  (0.2ml, 25 μg/ml, Sigma) through this indwelling cannula. Baroreceptors were 
stimulated by an intravenous injection of phenylephrine45 (0.2ml, 25 µg/ml, Sigma). As a control, the 
same volume of saline was also injected at the beginning of the experiment and was shown not to evoke 
any change in the recorded variables.  
At the beginning of the experimental protocol, and upon parameters stabilization, a recording of 
5min was taken for further autonomic evaluation. There was an interval of, at least, 3 min between 
each provocation to allow the recovery to basal values. Throughout the experiment, blood pressure 
(BP), ECG, heart rate (HR), tracheal pressure (TP) and respiratory frequency (RF) were continuously 
monitored and recorded (PowerLab, ADInstruments).  
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At the end of the experimental protocol, blood was collected from the femoral artery for BLL by 
atomic absorption spectroscopy (n=2). The guidelines for BLL monitoring in human children consider a 
value superior to 5 μg/dL to be harmful to human health5,6,18. 
The animal was, then, sacrificed with an overdose of anaesthetic. The brain was carefully 
removed and maintained 4% paraformaldehyde in phosphate buffer (PBS) (pH 7.4) at 4°C overnight, 
after which, was immersed in increasing concentrations of sucrose, of 15% and 30%. Subsequently, the 
brain was embedded in gelatine (7.5% gelatine in 15% sucrose solution) and frozen with liquid nitrogen 
and 2-metilbutane (Sigma-Aldrich, UK) for further histological procedures. 
 
Data acquisition and analysis 
All the recorded variables were acquired at 1 kHz, amplified and filtered (Neurolog, Digitimer; 
Powerlab, ADInstruments). For the recorded variables, the baseline values were taken immediately 
before the beginning of each type of stimulation. 
I. Baro- and chemoreceptor reflex analysis 
To evaluate the baroreceptor reflex function, the baroreceptor reflex gain (BRG) has been 
quantified, calculating the variation of HR in relation to mean BP variation: 𝛥𝛥𝛥𝛥𝛥𝛥 ⁄ 𝛥𝛥𝛥𝛥𝛥𝛥 upon 
phenylephrine provocation.  
The evaluation of the chemoreceptor response elicited by intra-carotid injection of lobeline 
was calculated through basal respiratory frequency (RF, in cpm) before [average of 30sec] and during 
lobeline stimulation, or, Δ chemoreflex (lob)= RF stimulation‑ RFbasal. 
 
II. Cardiovascular variability 
Heart rate and blood pressure variabilities are indirect methods for non-invasive evaluation of 
autonomic nervous system. Systolic blood pressure and R-R intervals were analysed, in periods of 3min, 
through discrete wavelet transform110–112 using an in-house software FisioSinal113, to calculate Low 
Frequencies (LF) and High Frequencies (HF). Low frequencies (LF; [0.15-0.6] Hz) obtained from systolic 
BP are a marker of sympathetic activity and high frequencies (HF; [0.6-2.0] Hz) obtained from R-R 
interval represent both parasympathetic and respiratory variations. The ratio LFsBP / HFRR represents 
the autonomic balance to the cardiovascular system. 
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3.5 IMMUNOFLUORESCENCE STUDIES 
Sample processing 
To address neuroinflammation and neurodegeneration, the hippocampus was identified (B=-
2.92 to -5.04), and the brain was sectioned around that region on a cryostat (Leica CM 3050S, Germany) 
and coronal slices (25µm) collected in a cryoprotectant solution (PBS, ethylene glycol and Glycerine) 
and stored at -20oC. For immunohistochemical studies, the slices were washed with TBS (3x/5min; Bio-
Rad, USA), placed in citrate buffer (Sigma-Aldrich, UK) at 90oC for 30min for antigen retrieval114. After 
cooling down to room temperature, the samples were washed with TBS (3x/5min) and treated with 
0.3% Triton X-100 (Sigma-Aldrich, UK) for 15 min. Sample blocking was then performed by 5% Goat 
Serum (BioWest, France) and 1% Bovine serum (VWR, USA) blocking solution for 1h, after which the 
incubation with primary antibodies over-night has been performed (concentrations and markers are 
shown in Table 2). 
Table 2 - List of primary antibodies used in immunohistochemistry protocol. 
 
At the second day of staining protocol, tissue slices were washed with TBS (3x/10min) and 
incubated with a secondary antibody, in concentrations presented in Table 3, for 1 hour at room 
temperature, after which, were washed (TBS; 3x/10min) and mounted in salinized SuperFrost® 
Microscope Slides treated with ProLong Gold Antifade with DAPI (Sigma-Adrich, UK), dried and stored 
at -20ºC until further visualisation and analysis of the dentate gyrus (DG).   
Table 3 - Secondary antibody used in the immunohistochemistry protocol. 
Secondary antibody Conjugate (Dilution) Supplier 
Goat anti-Rabbit IgG (H + L) 
Secondary antibody 
Alexa Fluor® 594 
(1:1000) Life Technologies - ThermoFisher 






(Dilution) Host Supplier 





Astrocytic marker Glial fibrillary acidic protein GFAP (1:500) 
Microglial marker 
 Ionized Ca binding adaptor molecule 1 
Iba-1 
(1:250) 
Synaptic marker Synaptophysin Syn (1:200) 
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Image acquisition 
Image acquisition was performed under a confocal point-scanning microscope (Zeiss LSM 880 
with Airyscan) (Table 4). All images where taken at DG level because it is known that this area receive 
the most number of input pathways to the hippocampus executing three main functions: (i) 
accumulating encoding of multiple sensory inputs, (ii) spatial pattern separation, and (iii) facilitation of 
encoding of spatial information based on its outputs to CA348. 
Table 4 – Image acquisition and quantification. 
Lasers, objectives and ZEN Software (Carl Zeiss, Germany) used for high-resolution fluorescence images of DG 
 
Marker 
Primary Ab Secondary Ab Conjugate Laser Objective Type of images 
Neuronal marker NeuN 594 HeNe594 (594 nm) 
20x, dry 
Snap optimal 








images in Z axis) Microglial marker Iba-1 




Subsequently the appropriate image acquisition, fluorescent images of GFAP, Iba-1 and 
Synaptophysin were analysed and quantified using Fiji115 open source software by specific features. 
Morphological categorization of GFAP and Iba-1 stained cells into various types of glial cells, form 
reactive to resting state cells was performed by comparison of the cells to the ones described in 
different sources55,116–118. Also, for GFAP and Iba-1, a manual quantification of positive cells was 
performed, using Z-stack images by Cell Counter plugin in the software to mark cells.  
Synaptophysin fluorescence intensity staining quantification was completed using ROI manager 
tool, choosing 5 regions of interest (ROIs), equal in size and shape and then normalized to a negative 
control image (sample obtained by incubation of secondary antibody without primary antibody for non-
specific binding quantification). 
Number of neurons in Neu-N stained tissue slides were quantified using an in-house software 
developed by Bioimaging facility of Instituto de Medicina Molecular João Lobo Antunes named 
Multichannel Cell Counter RGB. Succinctly, single-cell nuclei were identified via DAPI staining 
thresholding and particle analysis, and dilated regions of interest (ROIs), based on a user-defined radius. 
For each channel and ROI, a staining was considered positive if a minimum number of pixels (usually 5, 
above a given threshold), and a filter for cell counting was defined based on staining. 
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3.6 STATISTICAL ANALYSIS  
 Data are expressed as mean ± SEM and plotted as the composite of the mean values of all 
subjects, unless otherwise specified. Normality distribution of the continuous variables was analysed 
with the Kolmogorov-Smirnov test (Lilliefors’ correction) and Levene's test was used for assessment of 
homogeneity of variance. For assessing data within the same group or between Pb group and the 
Control group at a specific timepoint (12, 20 and 28 weeks), Student’s t-Test for paired or unpaired 
observations, respectively, was used.  
 Comparisons between groups (PbS vs. PbP vs PbI) were performed using a "repeated measures" 
analysis of variance (ANOVA) with Tukey’s multiple comparison. 
 A value of p < 0.05 was considered statistically significant. Data were analysed using GraphPad 
Prism 6 (GraphPad Software Inc, USA). 
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4 RESULTS 
4.1 LONG - TERM LEAD EXPOSURE PROTOCOL (PBP) 
The animal model of long-term lead exposure evaluates the behavioural, overall functional and 
hippocampal histological consequences of a continuous exposure of animals to lead since the foetal 
period until 28 weeks after birth. Animals were divided into three groups in accordance to the time of 
evaluation: 12, 20 and 28 weeks. 
Effect on metabolic parameters and BLL 
The weight of the animals, evaluated at three different time-points, did not change significantly 
in animals under long-term lead exposure protocol. Animals exposed to lead until 12 weeks ingest more 
water and less food, without alterations in the urine and faeces excretion. At 20 weeks of age no 
significant differences were observed, however in the animals exposed to lead until 28 weeks, a small 
increase in the water intake was detected, without an increase in urine production (Table 5). 
All the metabolic parameters evaluated in CTL groups, at three different time-points, did not 
change significantly. 
 Regarding the blood lead levels, Pb animals presented a high lead concentration at 20 and 28 
weeks of age, without BLL evaluation at 12 weeks (see Table 5 for values). 
 
Table 5 – Values of metabolic parameters and BLL in CTL and PbP groups at 12, 20 and 28 weeks of age. 
Values are presented as mean ± SEM. n=10/group; *p < 0.05; **p < 0.01. 











na 358 ± 34 25 ± 1 24 ± 3 19 ± 1 12 ± 1 
Pb na 345 ± 39 22 ± 1* 32 ± 3* 15 ± 1 9 ± 1 
CTL 20 
weeks 
< 0.1 386 ± 41 23 ± 3 39 ± 3 17 ± 2 12 ± 1 
PbP 28 ± 2.3 390 ± 42 24 ± 2 33 ± 2 20 ± 3 10 ± 1 
CTL 28 
weeks 
< 0.1 368 ± 36 24 ± 2 24 ± 2 11 ± 1 8 ± 1 
PbP 21 ± 10.7 434 ± 50 24 ± 3 30 ± 2* 16 ± 3 8 ± 1 
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Effect on blood pressure, heart rate and respiratory frequency  
Long-term lead exposure significantly increased mean blood pressure values, mainly due to the 
continuous increase of systolic and diastolic blood pressure through time. These hypertensive values 
were maintained between 20 and 28 weeks. Heart rate apparently did not account for those changes, 
since they did not change significantly during the continuously lead exposure. The changes of 
respiratory frequency follow the inverse profile of blood pressure (Figure 9; see Table 6 for values).  
 
Figure 9 – Basal physiological parameters evaluation of PbP and CTL protocols at 12, 20 and 28 weeks  
Systolic (A), diastolic (B) and mean (C) blood pressures, heart rate (D) and respiratory frequency (E).  
Values are mean ± SEM. ***p < 0.001; ****p < 0.0001. 
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Table 6 – Values of basal physiological parameters of PbP and CTL groups at 12, 20 and 28 weeks.  
Values are presented as mean ± SEM. n=10/group; ***p < 0.001; §p < 0.0001. 
 
Group Age 




(cpm) Systolic  Diastolic Mean 
CTL 12 
weeks 
125 ± 7 91 ± 7 113 ± 4 432 ± 7 78 ± 2 
Pb 164 ± 6*** 129 ± 4§ 141 ± 4§ 395 ± 27 113 ± 6§ 
CTL 20 
weeks 
137 ± 4 104 ± 4 119 ± 3 433 ± 10 81 ± 3 
PbP 171 ± 4§ 155 ± 4§ 163 ± 4§ 429 ± 6 81 ± 3 
CTL 28 
weeks 
120.1 ± 10.76 90 ± 7 104 ± 8 433 ± 27 60 ± 3 
PbP 171 ± 4§ 148 ± 4§ 157 ± 4§ 411 ± 9 68 ± 2 
 
 
Effect on baroreceptor and chemoreceptor reflexes 
Baroreceptor function seems to have undergone a remodelling process along time. In fact, the 
baroreflex gain decreased until 20 weeks, from which was kept without significant changes, suggesting 
that the putative remodelling process that was ongoing since early life to accommodate the increases 
in blood pressure has terminated.  
Long-term exposure to lead was responsible for an augmentation of the carotid chemoreflex 
sensitivity at 12 weeks that has been aggravated until 20 weeks of age and then maintained with the 
same profile until the end of exposure (28 weeks).  
The temporal evolution of both baroreceptor and chemoreceptor reflexes changes due to 
prolonged lead exposure is represented in Figure 10 and values in Table 7.  
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Figure 10 – Baroreceptor and chemoreceptor reflex evaluation of PbP and CTL protocols at 12, 20 and 28 weeks.  
Baroreflex gain (A) and chemoreflex sensitivity (B). Values are mean ± SEM; *p < 0.05; **p < 0.01. 
 
Table 7 – Values of baroreflex gain and chemoreflex sensitivity of PbP and CTL groups at 12, 20 and 28 weeks.  
Values are presented as mean ± SEM n=10/group; *p < 0.05; **p < 0.01. 
 





0.53 ± 0.10 15 ± 2.6 
Pb 0.27 ± 0.03* 22 ± 1.8* 
CTL 20 
weeks 
0.76 ± 0.11 20 ± 1.1 
PbP 0.39 ± 0.07* 31 ± 3.8** 
CTL 28 
weeks 
0.65 ± 0.07 14 ± 1.5 
PbP 0.37 ± 0.03** 25 ± 2.1** 
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Effect on autonomic output measured indirectly 
Autonomic function is impaired since earlier life. This impairment, expressed mainly in the 
sympathetic tone increase (LF band), is observed at 12 and 28 weeks, which contributed to the 
autonomic balance (LF/HF ratio) increase at 12 weeks. Interestingly, in opposition to other clinical 
conditions, in which the autonomic system is provoked for further adaptation leading to sympathetic 
overactivation independently of the parasympathetic tone (HF band), in this case, the activity of both 
peripheral branches follow the same incremental tendency changes resulting in a decrease of 
autonomic balance seen at 20 and 28 weeks of age.  
The time evolution of the LF, HF and LF/HF parameters for the 3 time-points of evaluation are 
presented in Figure 11 and values in Table 8. 
 
Figure 11 – Autonomic function evaluation of PbP and CTL protocols at 12, 20 and 28 weeks  
Low frequency band– LF (A), high frequency band - HF (B) and LF/HF index (C) are presented.  
Values are mean ± SEM; *p < 0.05. 
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Table 8 – Values of autonomic output measure indirectly of PbP and CTL groups at 12, 20 and 28 weeks 
Values are presented as mean ± SEM. n=10/group; *p < 0.05. 







1.015 ± 0.16 0.85 ± 0.37 2.49 ± 0.82 
Pb 2.34 ± 0.47* 0.56 ± 0.23 6.20 ± 1.29* 
CTL 20 
weeks 
0.85 ± 0.09 0.72 ± 0.08  0.93 ± 0.19 
PbP 1.37 ± 0.39 0.65 ± 0.076 1.41 ± 0.52 
CTL 28 
weeks 
1.05 ± 0.23 0.97 ± 0.25 0.88 ± 0.25  
PbP 2.02 ± 0.32* 1.04 ± 0.11 1.61 ± 0.25 
 
 
Effect on behavioural parameters 
Anxiety, locomotion and exploratory activity 
Long-term exposure to lead provokes irreversible anxiety behaviour in the animals through life 
that aggravates with the passing time. However, the initial time of exposure was the most relevant for 
the behavioural change. This behaviour was inferred by the reduction of the presence time in the open 
arms of the EPM apparatus thus, increasing the presence time in the closed arms of the maze. Also, 
variations in the number of entries that were observed are coherent with the presence time percentage 
changes, characteristic of an anxiety behaviour due to long-term lead exposure (see Figure 12; and 
Table 9 for values). 
Long-term lead exposure also induced some significant changes in the exploratory behaviour of 
the animals that was evaluated by OFT, leading to poor exploration and increasing the anxiety levels of 
the subjects since earlier life. These exploratory behaviour modifications were recovered through life 
(animals do not show changes in the presence time percentage in the central zone of the arena at 28 
weeks of age).  Also, the exposure to lead in the early stages of life is a cause of a hyperactive behaviour 
in the animals that was also recovered at 28 weeks. This change was inferred by the augmented values 
of the average velocity parameter in the Pb-exposed animals at 12 and 20 weeks of age thus increasing 
the total travelled distance of the animals in the arena (see Figure 13; and Table 10 for values). 
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Figure 12 – Anxiety behaviour assessment by EPM of PbP and CTL protocols at 12, 20 and 28 weeks  
Presence time percentage (A) and number of entries (B) in open and closed arms of the maze are presented.  
Values are mean ± SEM; *p < 0.05; ***p < 0.001; ****p < 0.0001. 
 
Table 9 – Values from anxiety behaviour assessment of PbP and CTL groups at 12, 20 and 28 weeks 
Values are presented as mean ± SEM. n=10/group; *p < 0.05; ***p < 0.001; §p < 0.0001. 
Group Age 
Presence Time (%) Number of entries 
Open Arms  Closed arms Open Arms  Closed arms 
CTL 12 
weeks 
29 ± 3.2 44 ± 1.8 7 ± 1.3 12 ± 1.0 
Pb 12 ± 2.3*** 60 ± 2.7*** 6 ± 1.2 33 ± 2.4§ 
CTL 20 
weeks 
21 ± 2.5 58 ± 5.4 5 ± 0.9 10 ± 1.1 
PbP 1 ± 0.4§ 91 ± 1.4§ 1 ± 0.4*** 13 ± 1.3 
CTL 28 
weeks 
27 ± 4.3 51 ± 6.8 6 ± 0.6 18 ± 3.5 
PbP 5 ± 1.4§ 77 ± 2.0*** 5 ± 0.7 12 ± 1.2* 
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Figure 13 – Locomotor and exploratory behaviour assessment by OFT of PbP and CTL protocols at 12, 20 and 28 weeks  
Presence time percentage in the centre (A), total number of entries (B), average velocity (C) and total travelled distance 
(D) are represented. Values are mean ± SEM; *p < 0.05; ***p < 0.001; ****p < 0.0001. 
 
Table 10 – Values of locomotor and exploratory activity assessment by OFT of PbP and CTL protocols at 12, 20 and 28 weeks  
Values are mean ± SEM. n=10/group; *p < 0.05; ***p < 0.001; §p < 0.0001. 
 









6 ± 1.0 63 ± 6.6 9.3 ± 0.9 2302 ± 171 
Pb 2 ± 0.6* 52 ± 7.5 17.9 ± 1.2§ 2350 ± 330 
CTL 20 
weeks 
3 ± 0.9 51 ± 4.3 11.0 ± 1.2 1993 ± 192 
PbP 1 ± 0.3* 45 ± 4.8 24.4 ± 1.2§ 4204 ± 331§ 
CTL 28 
weeks 
1 ± 0.4 39 ± 4.6 19.4 ± 3.2 2998 ± 105 
PbP 2 ± 0.2 68 ± 4.5*** 13.5 ± 1.4 2380 ± 232 
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Effect on memory 
Spatial working memory 
The spatial working memory seems not to be primary affected by the persistent lead exposure 
since foetal period and through lifetime, which was inferred from the lack of alterations in the 
spontaneous alternation behaviour in the animals that were exposed to lead. Also, no changes were 
observed in the exploration behaviour while performing the Y-Maze test, which could be a confounding 
factor for data interpretation.  
The time evolution of the spontaneous alterations percentage and the total number of entries 
parameters of the 3 periods of evaluation are presented in Figure 14 and values in Table 11. 
 
Figure 14 – Spatial working memory evaluation by Y-Maze test of PbP and CTL protocols at 12, 20 and 28 weeks  
Spontaneous alternations percentage (A) and the total number of entries in the arms (B) are presented.  
Values are mean ± SEM. 
 
Table 11 – Values from spatial working memory evaluation by Y-Maze test of PbP and CTL groups at 12, 20 and 28 weeks 
Values are presented as mean ± SEM. n=10/group. 
Group Age Spontaneous alternations (%)  Total number of entries 
CTL 12 
weeks 
67 ± 2.5 26 ± 1.6 
Pb 66 ± 3.7 23 ± 1.6 
CTL 20 
weeks 
64 ± 3.8 22 ± 2.4 
PbP 63 ± 2.6 20 ± 1.3 
CTL 28 
weeks 
66 ± 2.1 26 ± 1.3 
PbP 60 ± 2.7 24 ± 1.9 
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Episodic long-term memory 
As it is seen in the Figure 15 and Figure 16 and in the Table 12, PbP group shows no novel object 
recognition (data of exploration time percentage), as the animals explore the two objects (sample and 
Novel) similarly in the testing day, in the contrary to the CTL group, even though, showing no significant 
differences between the novelty recognition indexes at 20 and 28 weeks of age, a more refined and 
sensitive to variability parameter.  
Therefore, exposure to lead in the early stages causes a long-term memory impairment through 
life, even though, some recovery seems to be happening over time, which could be indicative of 
remodelling and adjustment processes to the lead presence within the regions responsible for long-
term memory-evoking.  
 
 
Figure 15 – Episodic long-term memory evaluation by NOR test of PbP and CTL protocols at 12, 20 and 28 weeks 
Training and testing exploration time percentage data from 12 weeks of age (A), 20 weeks of age (B) and 28 weeks of 
age (C) are presented. Values are mean ± SEM; *p < 0.05 (paired). 
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Figure 16 – Novelty recognition index data of PbP and CTL protocols at 12, 20 and 28 weeks  
Values are mean ± SEM; ***p < 0.001 (unpaired). 
 
 
Table 12 – Values of episodic long-term memory evaluation by NOR test of PbP and CTL groups at 12, 20 and 28 weeks 
Values are presented as mean ± SEM. n=10/group; $p < 0.05, (paired); ***p < 0.001 (unpaired). 
Group Age 




S S’ S N 
CTL 12 
weeks 
53 ± 2.8 47 ± 2.8 45 ± 1.7 55 ± 1.7$ 0.26 ± 0.06 
Pb 48 ± 2.5 52 ± 2.5 51 ± 1.9 49 ± 1.9 -0.04 ± 0.04*** 
CTL 20 
weeks 
58 ± 4.8 42 ± 4.8 43 ± 2.9 57 ±2.9$ 0.19 ± 0.06 
PbP 51 ± 2.5 49 ± 2.5 48 ± 3.6 52 ± 3.6 0.04 ± 0.07 
CTL 28 
weeks 
47 ± 3.7 53 ± 3.7 42 ± 2.3 58 ± 2.3$ 0.16 ± 0.05 
PbP 51 ± 1.8 49 ± 1.8 45 ± 2.9 55 ± 2.9 0.10 ± 0.06 
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Effect on morphofunctional processes in dentate gyrus subregion of the hippocampus 
Neurons 
Data from NeuN staining (see Figure 17 and Table 13) showed that long-term exposure to lead 
seem to provoke some tendency to augmentation of the neurodegenerative processes in dentate gyrus 
hippocampal region.  
 
Figure 17 – Detection and quantification of NeuN in DG hippocampal area of PbP and CTL protocols at 12, 20 and 28 weeks 
Confocal images (A) and quantitative analysis data (B) are represented.  




Data from Syn staining (see Figure 18 and Table 13) showed that a continuous Pb exposure from 
the early stages of life leads to increased synaptic processes in the hippocampus at 20 weeks of age, 
that seem to undergo a slow recovery through time, even though, not complete at 28 weeks of age. 
This synaptic overexcitation could be a cause of some general behavioural changes that were observed 
in the animals permanently exposed to lead.  
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Figure 18 – Detection and quantification of Syn in DG hippocampal area of PbP and CTL protocols at 12, 20 and 28 weeks 
Confocal images (A) and quantitative analysis data (B) are represented.  




Data from GFAP staining (see Figure 19 and Table 13) showed that long-term exposure to lead 
drastically affects the astrocytic cells, changes that persist through the whole time of exposure to lead, 
both in morphological and functional levels. Reactive astrogliosis (characterized by astrocytes marked 
with GFAP staining that are denser and upregulated for the marker, showing hypertrophic branches), 
which is reminiscent of chronic neuroinflammatory mechanisms and alterations in the tripartite 
synaptic processes for neuronal communication presence in the hippocampus area.   
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Figure 19 – Detection and quantification of GFAP in DG hippocampal area of PbP and CTL protocols at 12, 20 and 28 weeks 
Confocal images (A) and quantitative analysis data (B) are represented. Scale bar is 50µm for staining images. Values are 
mean ± SEM; **p < 0.01; ***p < 0.001. 
 
Microgliosis 
No visible alterations at the morphological level of the microglial cells were observed in animals 
that were permanently exposed to lead.  In fact, data from Iba-1 staining (see Figure 20 and Table 13) 
showed that microglia is ramified, with small cell bodies and numerous long branching processes. 
However, an increased number of these cells at both 20 and 28 weeks was observed, which is evocative 
of microglial activation promoting long-lasting pro-neuroinflammatory processes that contribute to 
central nervous system protection from the adverse effects of lead exposure.  
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Figure 20 – Detection and quantification of Iba-1 in DG hippocampal area of PbP and CTL protocols at 12, 20 and 28 weeks 
Confocal images (A) and quantitative analysis data (B) are represented. Scale bar is 50µm for staining images. Values are 
mean ± SEM; *p < 0.05; **p < 0.01. 
 
Table 13 – Values of NeuN, Syn, GFAP and Iba-1 stainings quantification in DG hippocampal area of PbP and CTL groups at 12, 
20 and 28 weeks 
















634 ± 50 42 ± 5.8 129 ± 3.5 29 ± 0.5 
PbP 613 ± 8.1 66 ± 5.3* 196 ± 4.6** 45 ± 3.8* 
CTL 28 
weeks 
702 ± 122.8 41 ± 4.2 134 ± 3.2 16 ± 2.1 
PbP 557 ± 58.7 58 ± 9.1 195 ± 6.3*** 39 ± 3.8** 
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4.2  SHORT - TERM LEAD EXPOSURE PROTOCOL (PBS) 
The animal model of short-term lead exposure evaluates the behavioural, overall functional and 
hippocampal morphofunctional alterations due to a short, single exposure of animals to lead since the 
foetal period until 12 weeks after birth, without being exposed during adulthood. Animals were divided 
into three groups in accordance to the time of evaluation: 12, 20 and 28 weeks. 
Effect on metabolic parameters and BLL 
Animals exposed to lead until 12 weeks of age and without any adult exposure do not present 
fluctuations in weight at different time-points of evaluations (at 12, 20 and 28 weeks of age) (Table 14). 
Regarding other metabolic parameters, it was found that just after lead exposure, at 12 weeks 
of age, a little food and water intake increase were observed in these animals, even though, without 
changes in the urine and faeces production. Interestingly, at 20 weeks of age, a small decrease in faeces 
production was reported, without food intake alterations, and at 28 weeks, an increase in urine 
excretion. All the metabolic parameters evaluated in CTL groups, at three different time-points, did not 
change significantly (Table 14). 
Regarding BLL, at 20 weeks, after an 8-week period lead abstinence, a low concentration of lead 
in the blood was observed in these animals. These levels are even lower after another 8 weeks without 
lead exposure, at 28 weeks of age. This can be explained by the increase in urine production, as it is 
one of the main routes of lead excretion (Table 14).  
 
Table 14 – Values of metabolic parameters and BLL of PbS and CTL groups at 12, 20 and 28 weeks of age. 
Values are presented as mean ± SEM. n=10/group; *p < 0.05; ***p < 0.001. 













na 358 ± 34 25 ± 1 24 ± 3 19 ± 1 12 ± 1 
Pb na 345 ± 39 22 ± 1* 32 ± 3* 15 ± 1 9 ± 1 
CTL 20 
weeks 
< 0.1 386 ± 41 23 ± 3 39 ± 3 17 ± 2 12 ± 1 
PbS 6 ± 0.7 390 ± 35 25 ± 1 34 ± 1 14 ± 1 8 ± 1*  
CTL 28 
weeks 
< 0.1 368 ± 36 24 ± 2 24 ± 2 11 ± 1 8 ± 1 
PbS 4 ± 0.4 445 ± 54 23 ± 2  31 ± 2 17 ± 1*** 9 ± 1 
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Effect on blood pressure, heart rate and respiratory frequency  
Short-term lead exposure since foetal period until 12 weeks of age significantly increases mean 
blood pressure values, due to the strong increase of both systolic and diastolic blood pressure values. 
A period of 8 weeks of lead abstinence was not sufficient for a decrease of blood pressure values, 
however, a longer period of 16 weeks without exposure to lead accounted for a small decrease of all 
blood pressure values, even though they maintained a hypertensive profile. 
Heart rate did not change with the presence of lead in the system and after its abstinence.  The 
tachypnoea is only observed at 12 weeks of age, when lead is still in high levels in the organism. After 
lead removal, a normal respiratory frequency was observed (Figure 21; Table 15).  
 
Figure 21 – Basal physiological parameters evaluation of PbS and CTL protocols at 12, 20 and 28 weeks  
Systolic (A), diastolic (B) and mean (C) blood pressures, heart rate (D) and respiratory frequency (E).  
Values are mean ± SEM; **p < 0.01; ***p < 0.001; ****p < 0.0001. 
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Table 15 – Values of basal physiological parameters of PbS and CTL groups at 12, 20 and 28 weeks 
Values are presented as mean ± SEM. n=10/group; **p < 0.01; ***p < 0.001; §p < 0.0001. 
 
Group Age 




(cpm) Systolic  Diastolic Mean 
CTL 12 
weeks 
125 ± 7 91 ± 7 113 ± 4 432 ± 7 78 ± 2 
Pb 164 ± 6*** 129 ± 4 § 141 ± 4 § 395 ± 27 113 ± 6 § 
CTL 20 
weeks 
137 ± 4 104 ± 5 119 ± 4 433 ± 11 82 ± 3 
PbS 204 ± 6 § 149 ± 4 § 169 ± 4 § 421 ± 7 81 ± 4 
CTL 28 
weeks 
120± 11 90 ± 8 104 ± 9 434 ± 27 60 ± 3 
PbS 157 ± 6** 121 ± 6** 136 ± 5** 394 ± 11 64 ± 4 
 
 
Effect on baroreceptor and chemoreceptor reflexes 
Baroreceptor reflex seems to be primarily affected by the lead exposure and rapidly recovers 
after lead removal. Actually, baroreflex gain suffered a huge decrease until 12 weeks (when animals 
were exposed to lead), slowly increasing after lead exposure was cessed, reaching normal values. 
Though, a period of 8 weeks was not sufficient for the baroreflex gain recovery to normal levels. A 
longer period of time was necessary for this process to occur and, only at 28 weeks of age, animals 
presented normal baroreflex gain values. 
In the contrary, the carotid chemoreceptor reflex, being affected by the lead exposure, did not 
undergo the remodelling and recovery processes. The increase of chemoreflex sensitivity that was 
found in the lead exposed animals at 12 weeks persisted through life, even after 16 weeks of lead 
abstinence.  
A temporal evolution of both baroreceptor and chemoreceptor reflexes changes due to a single, 
short-term exposure are presented in Figure 22 and values in Table 16.  
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Figure 22 – Baroreceptor and chemoreceptor reflex evaluation of PbS and CTL protocols at 12, 20 and 28 weeks  
Baroreflex gain (A) and chemoreflex sensitivity (B).  
Values are mean ± SEM; *p < 0.05; **p < 0.01. 
 
Table 16 – Values of baroreflex gain and chemoreflex sensitivity of PbS and CTL groups at 12, 20 and 28 weeks 
Values are presented as mean ± SEM. n=10/group; *p < 0.05; **p < 0.01. 
 





0.53 ± 0.10 15 ± 2.6 
Pb 0.27 ± 0.03* 22 ± 1.8* 
CTL 20 
weeks 
0.77 ± 0.11 20 ± 1.1 
PbS 0.49 ± 0.04* 31 ± 1.8** 
CTL 28 
weeks 
0.66 ± 0.07 14 ± 1.5 
PbS 0.52 ± 0.04 27 ± 2.9** 
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Effect on autonomic output measured indirectly 
In the animals that were exposed to lead until 12 weeks, the sympathetic autonomic function 
output (evaluated by the LF band) follows the same pattern of the baroreflex gain changes. The 
maximum increase of the LF band was observed shortly after lead exposure and it was slowly recovering 
through time without exposure to lead, reversing into values within normal range after a 16-week 
absence of lead (at 28 weeks). The HF band that accounts for the parasympathetic nervous system was 
not changed at the evaluated time-points. 
Due to the changes in the LF band, the LF/HF index (representative of the autonomic output) 
suffered an increase during lead exposure that was reversed after lead was removed from the diet, 
becoming normal after a long period of lead abstinence (i.e., ˃ 16 weeks). 
The time evolution of the LF, HF and LF/HF parameters of the 3 periods of evaluation are 
presented in Figure 23 and the values in Table 17. 
 
Figure 23 – Autonomic function evaluation of PbS and CTL protocols at 12, 20 and 28 weeks  
Low frequency band– LF (A), high frequency band - HF (B) and LF/HF index (C) are presented.  
Values are mean ± SEM; *p < 0.05, **p < 0.01. 
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Table 17 – Values of autonomic output measure indirectly of PbS and CTL groups at 12, 20 and 28 weeks 
Values are presented as mean ± SEM. n=10/group; *p < 0.05; **p < 0.01. 







1.02 ± 0.16 0.85 ± 0.37 2.49 ± 0.82 
Pb 2.34 ± 0.47* 0.56 ± 0.23 6.20 ± 1.29* 
CTL 20 
weeks 
0.86 ± 0.09 0.72 ± 0.08  0.93 ± 0.19 
PbS 1.81 ± 0.29** 0.62 ± 0.07 2.76 ± 0.57** 
CTL 28 
weeks 
1.05 ± 0.23 0.97 ± 0.25 0.88 ± 0.25 
PbS 1.15 ± 0.18 1.16 ± 0.17 0.94 ± 0.22  
 
Effect on behavioural parameters 
Anxiety, locomotion and exploratory activity 
Anxiety levels were increased due to the sort-term lead exposure for 12 weeks and through life 
course, even after lead was absent for a long period of time (16 weeks). Thus, the initial time of 
exposure was of significant relevance for this behavioural alteration. This behaviour was inferred by the 
reduction of the presence time in the open arms of the EPM apparatus thus, increasing the presence 
time in the closed arms of the maze. Though, the number of entries in the open arms were not 
significantly different of those of the controls, the number of entries in the closed arms were increased 
at 12 weeks of age which shows that animals were moving in the maze, without choosing the open 
arms. In the contrary, at 28 weeks, animals preferred to stay in the closed arms, without challenging 
themselves to move to the open arms (see Figure 24; and Table 18 for values). 
Lead exposure induced some significant changes in the exploratory behaviour of the animals that 
was evaluated by OFT, leading to poor exploration and increasing the anxiety levels of the subjects just 
after the terminus of exposure (data at 12 weeks). These alterations were recovered through life when 
lead was removed from the drinking diet (animals do not show changes in the presence time 
percentage in the central zone of the arena). Also, the exposure to lead in the early stages of life is a 
cause of a hyperactive behaviour in the animals that was also recovered in the life course, after lead 
removal (increased values of the average velocity parameter in the Pb-exposed animals at 12 weeks of 
age). Though, lead does not cause alterations in the locomotor activity (total travelled distance is similar 
to controls) (see Figure 25 and Table 19 from values from OFT evaluation).  
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Figure 24 – Anxiety behaviour assessment by EPM of PbS and CTL protocols at 12, 20 and 28 weeks  
Presence time percentage (A) and number of entries (B) in open and closed arms of the maze are presented.  
Values are mean ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. 
 
Table 18 – Values from anxiety behaviour assessment of PbS and CTL groups at 12, 20 and 28 weeks 
Values are presented as mean ± SEM. n=10/group; *p < 0.05; **p < 0.01; ***p < 0.001; §p < 0.0001. 
 
Group Age 
Presence Time (%) Number of entries 
Open Arms  Closed arms Open Arms  Closed arms 
CTL 12 
weeks 
29 ± 3.2 44 ± 1.8 7 ± 1.3 12 ± 1.0 
Pb 12 ± 2.3*** 60 ± 2.7*** 6 ± 1.2 33 ± 2.4§ 
CTL 20 
weeks 
21 ± 2.5 58 ± 5.3 5 ± 0.9 10 ± 1.0 
PbS 7 ± 2.2** 73 ± 3.2* 7 ± 0.7 12 ± 1.2 
CTL 28 
weeks 
27 ± 4.3 51 ± 6.8 6 ± 0.6 18 ± 3.5 
PbS 15 ± 2.7* 65 ± 3.8 5 ± 0.9 8 ± 0.9** 
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Figure 25 – Locomotor and exploratory behaviour assessment by OFT of PbS and CTL protocols at 12, 20 and 28 weeks  
Presence time percentage in the centre (A), Total number of entries (B), average velocity (C) and total travelled distance 
(D) are represented. Values are mean ± SEM; *p < 0.05; ****p < 0.0001. 
 
Table 19 – Values from locomotor and exploratory activity assessment by OFT of PbS and CTL protocols at 12, 20 and 28 weeks  
Values are mean ± SEM. n=10/group; *p < 0.05; §p < 0.0001. 









6 ± 1.0 63 ± 6.6 9 ± 0.9 2302 ± 171 
Pb 2 ± 0.6* 52 ± 7.5 18 ± 1.2§ 2350 ± 330 
CTL 20 
weeks 
3 ± 0.9 51 ± 4.3 11 ± 1.2 1993 ± 192 
PbS 2 ± 0.4 42 ± 6.4 13 ± 2.8 2013 ± 214 
CTL 28 
weeks 
1 ± 0.4 39 ± 4.6 19 ± 3.2 2998 ± 105 
PbS 1 ± 0.2 28 ± 6.7 17 ± 2.5 2976 ± 507 
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Effect on memory 
Spatial working memory 
A lack of alterations in the spontaneous alternation behaviour in the animals that were exposed 
to lead until 12 weeks of age is indicative of no alterations in the spatial working memory in these 
animals. Interestingly, at 28 weeks of age, PbS group present a reduction of the total number of entries, 
and no changes in the spontaneous alternations behaviour, which favours the hypotheses that lead 
does not primarily affect the spatial working memory. Even though, its removal is favourable for a 
memory improvement (see Figure 26, and Table 20 for values of the 3 time-points of evaluation). 
 
Figure 26 – Spatial working memory evaluation by Y-Maze test of PbS and CTL protocols at 12, 20 and 28 weeks  
Spontaneous alternations percentage (A) and the total number of entries in the arms (B) are presented.  
Values are mean ± SEM; *p < 0.05. 
 
Table 20 – Values from spatial working memory evaluation by Y-Maze test of PbS and CTL groups at 12, 20 and 28 weeks 
Values are presented as mean ± SEM. n=10/group; *p < 0.05. 
Group Age Spontaneous alternations (%)  Total number of entries 
CTL 12 
weeks 
67 ± 2.5 26 ± 1.6 
Pb 66 ± 3.7 23 ± 1.6 
CTL 20 
weeks 
64 ± 3.8 22 ± 2.4 
PbS 55 ± 3.6 21 ± 1.3 
CTL 28 
weeks 
66 ± 2.1 26 ± 1.3 
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Episodic long-term memory 
The episodic long-term memory is strongly affected by the lead exposition at the early stages 
(at 12 weeks). No recovery of these alterations has been observed after a period of 8 weeks without 
lead exposure, with lead continuing its nefarious effects in memory. However, a longer period of time 
without exposure seem to culminate in some recovery of this alterations to normality, as seen by the 
novelty recognition data, even though animals do not recognise the novel object at the testing day 
when exploration time percentage is calculated, contrary to controls that explore the novelty object for 
more time.  
Data of the exploration time percentage at 12, 20 and 28 weeks is shown in Figure 27, of the 
novel recognition index in Figure 28 and values of both parameters at the 3 time-points of evaluation 
are represented in Table 21. 
 
Figure 27 – Episodic long-term memory evaluation by NOR test of PbS and CTL protocols at 12, 20 and 28 weeks 
Training and testing exploration time percentage data from 12 weeks of age (A), 20 weeks of age (B) and 28 weeks of 
age (C) are presented. Values are mean ± SEM; *p < 0.05 (paired).  
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Figure 28 – Novelty recognition index data of PbS and CTL protocols at 12, 20 and 28 weeks  
Values are mean ± SEM; ***p < 0.001 (unpaired). 
 
 
Table 21 – Values of episodic long-term memory evaluation by NOR test of PbS and CTL groups at 12, 20 and 28 weeks 
Values are presented as mean ± SEM. n=10/group; $p < 0.05 (paired); ***p < 0.01 (unpaired).  
Group Age 




S S’ S N 
CTL 12 
weeks 
53 ± 2.8 47 ± 2.8 45 ± 1.7 55 ± 1.7$ 0.26 ± 0.06 
Pb 48 ± 2.5 52 ± 2.5 51 ± 1.9 49 ± 1.9 -0.04 ± 0.04*** 
CTL 20 
weeks 
58 ± 4.8 42 ± 4.8 43 ± 2.9 57 ±2.9$ 0.19 ± 0.06 
PbS 44 ± 5.3 56 ± 5.3 52 ± 2.5 48 ± 2.5 -0.10 ± 0.03*** 
CTL 28 
weeks 
47 ± 3.7 53 ± 3.7 42 ± 2.3 58 ± 2.3$ 0.16 ± 0.05 
PbS 46 ± 7.9 54 ± 7.9 48 ± 6.6 52 ± 6.6 0.03 ± 0.13 
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Effect on morphofunctional processes in dentate gyrus subregion of the hippocampus 
Neurons 
Data from NeuN staining (see Figure 29 and Table 22 for values) showed that short-term 
exposure to lead seem not be affecting neurodegenerative processes in dentate gyrus hippocampal 
region, even after long periods of lead abstinence (namely, after 8 e 16 weeks). 
 
Figure 29 – Detection and quantification of NeuN in DG hippocampal area of PbS and CTL protocols at 12, 20 and 28 weeks 
Confocal images (A) and quantitative analysis data (B) are represented.  




Data from Syn staining (see Figure 30 and Table 22 for values) showed that, at 20 weeks of age, 
animals that underwent an exposure to lead until 12 weeks and were withdrawn from that drinking 
solution for 8 weeks have a reduction in the synaptic transmission. Though, a longer period of lead 
abstinence (for 16 weeks) permitted the recovery of synaptic transmission similar to controls (at 28 
weeks of age). 
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Figure 30 – Detection and quantification of Syn in DG hippocampal area of PbS and CTL protocols at 12, 20 and 28 weeks 
Confocal images (A) and quantitative analysis data (B) are represented.  
Scale bar is 20µm for staining images. Values are mean ± SEM; *p < 0.05.  
 
Astrogliosis 
Data from GFAP staining (see Figure 31 and Table 22 for values) showed that an exposure to 
lead in the early stages of life drastically affects the astrocytic cells, at morphological and functional 
levels, changes that persist through life, even after a prolonged period of lead abstinence. 
In PbS group, the astrocytic cells are in the activated state within the hippocampus (astrocytes 
marked with GFAP staining are dense and upregulated, with hypertrophic branches), that is reminiscent 
of chronic neuroinflammatory mechanisms and alterations in the tripartite synaptic processes for 
neuronal communication, even though lead was removed from the drinking water of the animals for 8 
or 16 weeks.   
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Figure 31 – Detection and quantification of GFAP in DG hippocampal area of PbS and CTL protocols at 12, 20 and 28 weeks 
Confocal images (A) and quantitative analysis data (B) are represented. Scale bar is 50µm for staining images.  




Data from Iba-1 staining (see Figure 32 and Table 22 for values) showed no visible alterations 
at the morphological level of the microglial cells, with microglia being in ramified state, small cell bodies 
and numerous long branching processes.  
However, even after a long period of time without lead exposure, an increased number of these 
cells were observed at both 20 and 28 weeks, which is evocative of the microglial activation, which 
becomes reactive, leading to long-lasting pro-neuroinflammatory mechanisms activation that acts to 
protect the central nervous system. 
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Figure 32 – Detection and quantification of Iba-1 in DG hippocampal area of PbS and CTL protocols at 12, 20 and 28 weeks 
Confocal images (A) and quantitative analysis data (B) are represented. Scale bar is 50µm for staining images.  
Values are mean ± SEM; *p < 0.05; **p < 0.01. 
 
Table 22 – Values of NeuN, Syn, GFAP and Iba-1 stainings quantification in DG hippocampal area of PbS and CTL groups at 12, 
20 and 28 weeks 
Values are presented as mean ± SEM. n=3/group; *p < 0.05; **p < 0.01; ***p < 0.001. 
 












634 ± 49.7 42 ± 5.8 129 ± 3.5 29 ± 0.5 
PbS 486 ± 87.8 23 ± 2.1* 184 ± 1.2*** 33 ± 0.9* 
CTL 28 
weeks 
702 ± 122.8 41 ± 4.2 134 ± 3.2 16 ± 2.1 
PbS 627 ± 80.3 51 ± 0.9 194 ± 3.3*** 28 ± 1.2** 
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4.3 INTERMITTENT LEAD EXPOSURE PROTOCOL (PBI) 
The intermittent lead exposure protocol evaluates the behavioural, overall functional and 
hippocampal morphofunctional alterations from a double exposure to lead, first exposure since the 
foetal period until 12 weeks after birth, and a second from 20 to 28 weeks of age, with a lead-free 
period in between (from 12 to 20 weeks). Animals were divided into three groups in accordance to the 
time of evaluation: 12, 20 and 28 weeks. 
Effect on metabolic parameters and BLL 
The weight of the animals, evaluated at three different time-points, did not change significantly 
in animals under intermittent lead exposure protocol. At 12 weeks of age, a little food and water intake 
increase were observed in these animals, even though, without changes in the urine and faeces 
production. At 20 weeks, only a small decrease in the faeces excretion was observed, that could also 
be one of the signs of some stress related to the metabolic cages. All the metabolic parameters 
evaluated in CTL groups, at three different time-points, and in PbI group evaluated at 28 weeks did not 
change significantly (Table 23). 
The levels of lead in the blood are decreased after an 8-week period of lead abstinence and 
strongly increase after a second exposure for 8 weeks (Table 23). 
 
Table 23 - Metabolic parameters of PbI and CTL groups at 12, 20 and 28 weeks of age. 
Values are presented as mean ± SEM. n=10/group; *p < 0.05. 













na 358 ± 34 25 ± 1 24 ± 3 19 ± 1 12 ± 1 
Pb na 345 ± 39 22 ± 1* 32 ± 3* 15 ± 1 9 ± 1 
CTL 20 
weeks 
< 0.1 386 ± 41 23 ± 3 39 ± 3 17 ± 2 12 ± 1 
PbI 6 ± 0.7 390 ± 35 25 ± 1 34 ± 1 14 ± 1 8 ± 1*  
CTL 28 
weeks 
< 0.1 368 ± 36 24 ± 2 24 ± 2 11 ± 1 8 ± 1 
PbI 21 ± 2.7 428 ± 50 24± 2 25 ± 2 11 ± 0.4 9 ± 2 
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Effect on blood pressure, heart rate and respiratory frequency  
Blood pressure is highly increased after the first exposure to lead from foetal period until 12 
weeks, without recovering to normotensive values at 20 weeks, after an 8-week period of lead 
abstinence. Nevertheless, the effect of a second exposure to lead in the adulthood (from 20 to 28 weeks 
of age) is not as nefarious as the first exposure, mainly seen in the diastolic blood pressure that is 
reduced at 28 weeks, however not reaching the normotensive values (Figure 33; Table 24). 
Heart rate did not change at the lead exposure and at lead abstinence periods. Respiratory 
frequency is only increased when high lead levels are present in the blood (at 12 weeks, after the first 
lead exposure and at 28 weeks, after the second exposure), fully recovering after lead removal. Also, 
the adult exposure to lead (second period of exposure) did not provoke a very strong increase in this 
parameter as seen in the first exposure (Figure 33; see Table 24 for values).   
 
Figure 33 – Basal physiological parameters evaluation of PbI and CTL protocols at 12, 20 and 28 weeks  
Systolic (A), diastolic (B) and mean (C) blood pressures, heart rate (D) and respiratory frequency (E).  
Values are mean ± SEM;*p < 0.05; ***p < 0.001; ****p < 0.0001. 
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Table 24 – Values of basal physiological parameters of PbI and CTL groups at 12, 20 and 28 weeks 
Values are presented as mean ± SEM. n=10/group; *p < 0.05; ***p < 0.001; §p < 0.0001. 
 
Group Age 




(cpm) Systolic  Diastolic Mean 
CTL 12 
weeks 
125 ± 7 91 ± 7 113 ± 4 432 ± 7 78 ± 2 
Pb 164 ± 6*** 129 ± 4§ 141 ± 4§ 395 ± 27 113 ± 6§ 
CTL 20 
weeks 
137 ± 4 104 ± 5 119 ± 4 433± 11 82 ± 3 
PbI 204 ± 6§ 149 ± 4§ 169 ± 4§ 421 ± 7 81 ± 4 
CTL 28 
weeks 
120 ± 11 90 ± 8 104 ± 9 433 ± 27 60 ± 4 
PbI 141 ± 2§ 108 ± 2* 124 ± 4* 404 ± 10 72 ± 2* 
 
Effect on baroreceptor and chemoreceptor reflexes 
Baroreceptor reflex is strongly affected by the lead presence in the system, suffering an 
impairment after the first lead exposure. The period of lead abstinence of 8 weeks was not sufficient 
for baroreflex gain to recover to its normal values and a second exposure to lead even potentiated 
more the impairment that was observed after the first exposure.  
The chemoreflex sensitivity is strongly increased after the first exposure at the developmental 
period, without suffering a remodelling and recovery processes after lead was removed. A second, adult 
exposure to lead, potentiated the increase in this parameter even more that the first exposure (Figure 
34, see Table 25 for values).  
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Figure 34 – Baroreceptor and chemoreceptor reflex evaluation of PbI and CTL protocols at 12, 20 and 28 weeks  
Baroreflex gain (A) and chemoreflex sensitivity (B). Values are mean ± SEM; *p < 0.05; **p < 0.01. 
 
Table 25 – Values of baroreflex gain and chemoreflex sensitivity of PbI and CTL groups at 12, 20 and 28 weeks 
Values are presented as mean ± SEM. n=10/group; *p < 0.05; **p < 0.01. 
 





0.53 ± 0.10 15 ± 2.6 
Pb 0.27 ± 0.03* 22 ± 1.8* 
CTL 20 
weeks 
0.76 ± 0.11 20 ± 1.1 
PbI 0.49 ± 0.04* 31 ± 1.8** 
CTL 28 
weeks 
0.66 ± 0.07 14 ± 1.5 
PbI 0.38 ± 0.03** 32 ± 4.4** 
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Effect on autonomic output measured indirectly 
Autonomic function is impaired since the early exposure to lead. A sympathetic overexcitation 
(increase in the LF band) was reported after the first, developmental exposure to lead. This increase in 
the LF band persisted even after a period of 8 weeks without lead exposure. Although, an exposure in 
the adulthood (from 20 to 28 weeks of age) did not increase the LF band, being at its normal range 
values. The HF band, representative of the parasympathetic nervous system, did not suffer significant 
alterations through the whole exposure protocol. 
By reason of the changes in the LF band, the LF/HF index (representative of the autonomic 
output) suffered an increase after first exposure and after the period of lead abstinence for 8 weeks, 
not suffering alterations after the second, adult exposure to lead. 
Time evolution of the LF, HF and LF/HF parameters and the values for the 3 periods of evaluation 
are presented in Figure 35 and Table 26. 
 
Figure 35 – Autonomic function evaluation of PbI and CTL protocols at 12, 20 and 28 weeks  
Low frequency band– LF (A), high frequency band - HF (B) and LF/HF index (C) are presented.  
Values are mean ± SEM; *p < 0.05, **p < 0.01. 
  
Results | Intermittent lead exposure protocol (PbI) characterization 
66   |   Liana Shvachiy 
 
Table 26 – Values of autonomic output measure indirectly of PbI and CTL groups at 12, 20 and 28 weeks 
Values are presented as mean ± SEM. n=10/group; *p < 0.05; **p < 0.01. 







1.02 ± 0.16 0.85 ± 0.37 2.49 ± 0.82 
Pb 2.34 ± 0.47* 0.56 ± 0.23 6.20 ± 1.29* 
CTL 20 
weeks 
0.86 ± 0.09 0.72 ± 0.08  0.93 ± 0.19 
PbI 1.81 ± 0.29** 0.62 ± 0.08 2.75 ± 0.57** 
CTL 28 
weeks 
1.05 ± 0.23 0.97 ± 0.25 0.88 ± 0.25  
PbI 1.40 ± 0.24 1.24 ± 0.34 0.47 ± 0.15 
 
 
Effect on behavioural parameters 
Anxiety, locomotion and exploratory activity 
Anxiety levels seem to be primarily increased after the first, early-life lead exposure, without 
recover to normal levels after the period of lead abstinence. A second, adult lead exposure seems not 
to affect as strongly this behaviour, even though, the stress levels were increased through the whole 
experimental protocol in these animals. This behaviour was inferred by the reduction of the presence 
time in the open arms of the EPM apparatus thus, consequently increasing the presence time in the 
closed arms of the maze. Though, the number of entries in the open arms were significantly different 
of those of the controls, the number of entries in the closed arms were increased at 12 weeks of age, 
which shows that animals were moving in the maze, without choosing the open arms. In the contrary, 
at 28 weeks, animals preferred to stay in the closed arms, without challenging themselves to move to 
the open arms (see Figure 36; and Table 27 for values). 
The developmental lead exposure (from foetal period until 12 weeks of age) seem to be the most 
nefarious for the exploratory behaviour alterations, leading to the anxiety and hyperactivity behaviours 
in the animals (decreased time in the centre and increased average velocity, respectively). However, 
both these alterations in the behaviour seem to be recovered when lead is removed from the diet and 
a second, adulthood exposure, not having a strong effect on these behaviours. The total number of 
entries and the total travelled distance of these animals did not change a lot through the whole 
experimental protocol (see Figure 37; and Table 28 for values). 
Intermittent lead exposure protocol (PbI) characterization| Results 
Liana Shvachiy   |   67 
 
 
Figure 36 – Anxiety behaviour assessment by EPM of PbI and CTL protocols at 12, 20 and 28 weeks  
Presence time percentage (A) and number of entries (B) in open and closed arms of the maze are presented.  
Values are mean ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. 
 
Table 27 – Values from anxiety behaviour assessment of PbI and CTL groups at 12, 20 and 28 weeks 
Values are presented as mean ± SEM. n=10/group; *p < 0.05; **p < 0.01***p < 0.001; §p < 0.0001. 
Group Age 
Presence Time (%) Number of entries 
Open Arms  Closed arms Open Arms  Closed arms 
CTL 12 
weeks 
29 ± 3.2 44 ± 1.8 7 ± 1.3 12 ± 1.0 
Pb 12 ± 2.3*** 60 ± 2.7*** 6 ± 1.2 33 ± 2.4§ 
CTL 20 
weeks 
21 ± 2.5 58 ± 5.3 5 ± 0.9 10 ± 1.1 
PbI 7 ± 2.2** 73 ± 3.2* 7 ± 0.7 12 ± 1.2 
CTL 28 
weeks 
27 ± 4.2 51 ± 6.8 6 ± 0.6 18 ± 3.5 
PbI 14 ± 2.8* 66 ± 6.4 3 ± 0.6** 9 ± 0.9** 
Results | Intermittent lead exposure protocol (PbI) characterization 
68   |   Liana Shvachiy 
 
 
Figure 37 – Locomotor and exploratory behaviour assessment by OFT of PbI and CTL protocols at 12, 20 and 28 weeks  
Presence time percentage in the centre (A), Total number of entries (B), average velocity (C) and total travelled 
distance, (D) are represented. Values are mean ± SEM; *p < 0.05; ****p < 0.0001. 
 
Table 28 – Values from locomotor and exploratory activity assessment by OFT of PbI and CTL protocols at 12, 20 and 28 weeks  
Values are mean ± SEM. n=10/group; *p < 0.05; §p < 0.0001. 









6 ± 1.0 63 ± 6.6 9 ± 0.9 2302 ± 171 
Pb 2 ± 0.6* 52 ± 7.5 18 ± 1.2 § 2350 ± 330 
CTL 20 
weeks 
3 ± 0.9 51 ± 4.3 11 ± 1.2 1993 ± 192 
PbI 2 ± 0.4 42 ± 6.4 13 ± 2.7 2013 ± 214 
CTL 28 
weeks 
1 ± 0.3 39 ± 4.6 19 ± 3.2 2998 ± 105 
PbI 1± 0.4 29 ± 3.9 17 ± 1.8 3152 ± 380 
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Effect on memory 
Spatial working memory 
A lack of alterations in the spontaneous alternation behaviour in the animals that were exposed 
to lead until 12 weeks of age, which is indicative of no alterations in the spatial working memory in 
these animals. Interestingly, at 28 weeks of age, animals that suffered an intermittent (double) lead 
exposure present a reduction of the total number of entries, and no changes in the spontaneous 
alternations behaviour, which favours the hypotheses that lead does not primarily affect the spatial 
working memory (see Figure 38, and Table 29 for values at the 3 evaluated time-points). 
 
Figure 38 – Spatial working memory evaluation by Y-Maze test of PbI and CTL protocols at 12, 20 and 28 weeks  
Spontaneous alternations percentage (A) and the total number of entries in the arms (B) are presented.  
Values are mean ± SEM; *p < 0.05. 
 
Table 29 – Values from spatial working memory evaluation by Y-Maze test of PbI and CTL groups at 12, 20 and 28 weeks 
Values are presented as mean ± SEM. n=10/group; *p < 0.05. 
  
Group Age Spontaneous alternations (%)  Total number of entries 
CTL 12 
weeks 
67± 2.5 26 ± 1.6 
Pb 66 ± 3.7 23 ± 1.6 
CTL 20 
weeks 
64 ± 3.8 22 ± 2.4 
PbI 55 ± 3.6 21 ± 1.3 
CTL 28 
weeks 
66 ± 2.1 26 ± 1.3 
PbI 67 ± 2.7 20 ± 2.2* 
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Episodic long-term memory 
The episodic long-term memory is strongly affected by the lead exposition at the early stages 
(exposure until 12 weeks). No recovery of these alterations has been observed after a period of 8 weeks 
without lead exposure, with lead continuing its nefarious effects in memory. However, an adult 
exposure to lead (from 20 to 28 weeks of age) seem not to affect the episodic long-term memory, as 
seen by the novelty recognition data, even though animals do not recognise the novel object at the 
testing day when exploration time percentage is calculated, contrary to controls that explore the 
novelty object for more time due to familiarization with the sample object.  
Data of the exploration time percentage at 12, 20 and 28 weeks is shown in Figure 39, of the 
novel recognition index in Figure 40 and values of both parameters at the 3 time-points of evaluation 
are represented in Table 30. 
 
Figure 39 – Episodic long-term memory evaluation by NOR test of PbI and CTL protocols at 12, 20 and 28 weeks 
Training and testing exploration time percentage data from 12 weeks of age (A), 20 weeks of age (B) and 28 weeks of 
age (C) are presented. Values are mean ± SEM; *p < 0.05 (paired).  
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Figure 40 – Novelty recognition index data of PbI and CTL protocols at 12, 20 and 28 weeks  
Values are mean ± SEM; ***p < 0.001 (unpaired). 
 
 
Table 30 – Values of episodic long-term memory evaluation by NOR test of PbI and CTL groups at 12, 20 and 28 weeks 
Values are presented as mean ± SEM. n=10/group; $p < 0.05 (paired); ***p < 0.01 (unpaired). 
Group Age 




S S’ S N 
CTL 12 
weeks 
53 ± 2.8 47 ± 2.8 45 ± 1.7 55 ± 1.7$ 0.26 ± 0.06 
Pb 48 ± 2.5 52 ± 2.5 51 ± 1.9 49 ± 1.9 -0.04 ± 0.04*** 
CTL 20 
weeks 
58 ± 4.8 42 ± 4.8 43 ± 2.9 57 ±2.9$ 0.19 ± 0.06 
PbI 44 ± 5.3 56 ± 5.3 52 ± 2.5 48 ± 2.5 -0.10 ± 0.03*** 
CTL 28 
weeks 
47 ± 3.7 53 ± 3.7 42 ± 2.3 58 ± 2.3$ 0.16 ± 0.05 
PbI 50 ± 4  50 ± 4 45 ± 10 55 ± 10 0.09 ± 0.19 
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Effect on morphofunctional processes in dentate gyrus subregion of the hippocampus 
Neurons 
Data from NeuN staining (see Figure 41 and Table 31 for values) showed that an intermittent 
exposure (early and adult) to lead seem not be affecting neurodegenerative processes in dentate gyrus 
hippocampal region, even after a period of 8 weeks without lead, and after the second exposure. 
 
Figure 41 – Detection and quantification of NeuN in DG hippocampal area of PbI and CTL protocols at 12, 20 and 28 weeks 
Confocal images (A) and quantitative analysis data (B) are represented.  




Data from Syn staining (see Figure 42 and Table 31 for values) showed that, at 20 weeks of age, 
animals that underwent an exposure to lead until 12 weeks and were withdrawn from that drinking 
solution for 8 weeks have a reduction in the synaptic transmission. A second lead exposure for 8 weeks 
potentiates this change even more, with a synaptic loss being even stronger at 28 weeks of age. 
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Figure 42 – Detection and quantification of Syn in DG hippocampal area of PbI and CTL protocols at 12, 20 and 28 weeks 
Confocal images (A) and quantitative analysis data (B) are represented.  
Scale bar is 20µm for staining images. Values are mean ± SEM; *p < 0.05; **p < 0.01.  
 
Astrogliosis 
Data from GFAP staining (see Figure 31 and Table 22 for values) showed that the first, early-life 
lead exposure primarily affects the astrocytic cells, even if a period of lead abstinence was present. A 
second exposure to lead does not potentiate the changes already present in these animals. 
The astrocytic cells are in the activated state within the hippocampus (astrocytes marked with 
GFAP staining are denser, showing hypertrophic branches and an upregulation for GFAP staining), that 
is reminiscent of chronic neuroinflammatory mechanisms and alterations in the tripartite synaptic 
processes for neuronal communication, changes that persist after lead-free period and after a second 
exposure (from 20 to 28 weeks of age).  
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Figure 43 – Detection and quantification of GFAP in DG hippocampal area of PbI and CTL protocols at 12, 20 and 28 weeks 
Confocal images (A) and quantitative analysis data (B) are represented.  
Scale bar is 50µm for staining images. Values are mean ± SEM; ***p < 0.001.  
 
Microgliosis 
Data from Iba-1 staining (see Figure 44 and Table 31 for values) showed no visible alterations 
at the morphological level of the microglial cells, with microglia being in ramified state, small cell bodies 
and numerous long branching processes at 20 weeks of age. However, after the second exposure, 
microglial cells became reactive, with loss of branches and upregulation for Iba-1. 
Also, an increased number of these cells at both 20 and 28 weeks was observed, which is 
evocative of the microglia activation, becoming reactive, promoting long-lasting pro-
neuroinflammatory processes that contribute to central nervous system protection. The period of lead 
abstinence of 8 weeks was not sufficient for microglial number to recover to normality and the second 
period potentiated the increase of these cells (evaluation at 28 weeks), which is evocative of microglial 
activation.  
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Figure 44 – Detection and quantification of Iba-1 in DG hippocampal area of PbI and CTL protocols at 12, 20 and 28 weeks 
Confocal images (A) and quantitative analysis data (B) are represented.  
Scale bar is 50µm for staining images. Values are mean ± SEM; *p < 0.05. 
 
Table 31 – Values of NeuN, Syn, GFAP and Iba-1 stainings quantification in DG hippocampal area of PbI and CTL groups at 12, 
20 and 28 weeks 
Values are presented as mean ± SEM. n=3/group; *p < 0.05; **p < 0.01; ***p < 0.001. 












634 ± 49.7 42 ± 5.8 129 ± 3.5 29 ± 0.5 
PbI 486 ± 87.8 23 ± 2.1* 184 ± 1.2*** 33 ± 0.9* 
CTL 28 
weeks 
702 ± 122.8 41 ± 4.2 134 ± 3.2 16 ± 2.1 
PbI 540 ± 53 18 ± 1.1** 192 ± 3.1*** 42 ± 3.2** 
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4.4 COMPARISON BETWEEN LONG-TERM (PBP), SHORT-TERM (PBS) AND INTERMITTENT (PBI) 
LEAD EXPOSURE PROFILES AT 28 WEEKS OF AGE 
After the physiological, behavioural and immunohistochemistry characterization of all lead 
exposure groups in three different timepoints (12, 20 and 28 weeks of age) and its comparison with a 
matching control group, a comparison between all these three developed lead exposure profiles was 
performed. In summary, the long-term lead exposure (PbP) was exposed from foetal period to 28 weeks 
of age through animal life, the short-term lead exposure (PbS) was exposed to a single lead exposure 
from foetal period until 12 weeks of age with no adult exposure until 28 weeks and, finally the 
intermittent lead exposure (PbI) suffered a double exposure, from foetal period until 12 weeks of age 
and an adult exposure from 20 to 28 weeks of age.  
 
Basal physiological differences between lead exposed groups 
Long-term lead exposure causes the highest increase in blood pressure, while the intermittent 
lead exposure causes the mildest blood pressure increase, without significant differences between heart 
rate and respiratory frequency values 
Some significant differences were reported regarding blood pressure values (Figure 45) 
between PbS (n=10) PbI (n=10) and PbP (n=10) groups (A). Concerning systolic blood pressure (sBP), 
only a significant difference was reported between PbI and PbP groups (**p < 0.01). Regarding the 
diastolic blood pressure (dBP), significant differences were reported between PbS and PbP groups 
(***p < 0.001) and PbI and PbP groups (****P < 0.0001). Also, significant differences were reported 
concerning the mean blood pressure (mBP) between PbS and PbP groups (**P <0.01) and PbI and PbP 
groups (****p < 0.0001). No significant differences between groups were observed between groups 
regarding both, heart rate (B) and respiratory frequency (C) (p > 0.05). 
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Figure 45 - Physiological parameters in PbS, PbI and PbP groups 
Significant differences were reported in blood pressure values between groups (A), However, no significant changes were 
reported in heart rate (B) and respiratory frequency (C). Values are mean ± SEM; **p < 0.01; ***p < 0.001; ****p < 0.0001. 
 
Baroreceptor and chemoreceptor reflexes differences between lead exposed groups 
Significant impairment of baroreflex was caused by permanent and intermittent lead exposures 
without changes in the chemoreflex sensitivity 
The baroreflex gain (A) was significant different between the PbS group and PbI group (PbS vs 
PbI - *p < 0.05) and the PbS and PbP groups (PbS vs PbP - *P<0.05), without significant differences 
between PbI and PbP groups (p > 0.05) (n=10/group, **p < 0.01).  
As for the chemoreflex sensitivity (B), no significant differences were reported between the three 
groups (n=10/group, p > 0.05). Data shown in Figure 46. 
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Figure 46 – Baroreceptor gain and chemoreflex sensitivity evaluation in PbS, PbI and PbP groups at 28 weeks 
Significant differences were reported between groups in the baroreflex gain (A). No significant differences were observed in 
the chemoreflex sensitivity (B). Values are mean ± SEM; *p < 0.05. 
 
Autonomic output differences between lead exposed groups  
Permanent lead exposure causes the strongest sympathoexcitation without any changes in the 
parasympathetic tone  
A significant difference was observed in LF parameter (A) by the PbP group, when compared to 
the PbS animals (n=10/group; *p < 0.05). No significant differences were reported in the HF (B) and 
LF/HF (C) parameters (p > 0.05), data shown in Figure 47. 
 
Figure 47 - Autonomic function evaluation of PbS, PbI and PbP groups at 28 weeks 
Low frequency band– LF (A), high frequency band - HF (B) and LF/HF index (C) are presented. A significant difference was 
observed in LF band in the PbP group when compared to the PbS group. No other significant modifications between groups 
were observed in the LF and HF bands and LF/HF index; *p < 0.05. 
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Behavioural differences between lead exposed groups 
Permanent lead exposure leads to a strong anxiety levels without changing the locomotor and 
exploratory activity 
In EPM test (Figure 48) and concerning the percentage of presence time (A), only a significant 
difference between PbS and PbP groups was observed regarding the percentage of time in the open 
arms (n=10/group; *p < 0.05). No significant differences were depicted in the percentage of time spent 
in closed arms and, also in the number of entries (B), either in the open and closed arms, between the 
three groups (P < 0.05). 
 
 
Figure 48 – Anxiety behaviour assessment by EPM test in PbS, PbI and PbP groups at 28 weeks 
A significant decrease of percentage of time was reported between PbS and PbP group (A) without any differences in the 
percentage of time in closed arms and number of entries in both, open and closed arms (B).   
Values are mean ± SEM; *p < 0.05. 
  
 The open field test performance of PbS, PbI and PbP groups is presented in Figure 49. Regarding 
the total number of entries (B), the significant differences between PbP and PbS group (n=10/group; 
***p < 0.0001) and PbP and PbI group (****p < 0.0001). No significant differences were observed in 
the presence time in the centre parameter (A) between groups. Also, no significant differences were 
reported in the total travelled distance (C) and average velocity (D) between the three groups. (NS p > 
0.05). 
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Figure 49 – Locomotor and exploratory activity assessment by OFT of PbS, PbI and PbP groups at 28 weeks 
Significant differences were found between PbP group and PbS and PbI groups (A). No changes were observed in the total 
travelled distance (B) and average velocity (C) between groups. Values are mean ± SEM; ****p < 0.0001. 
 
Memory differences between lead exposed groups 
Lead exposure profiles caused no changes in the working and episodic long-term memory 
Spatial working learning and memory assessment performance is presented in Figure 50. 
Regarding the percentage of spontaneous alternation (A) and total number of entries (B) calculated 
from Y-Maze test, no significant differences between PbS, PbI and PbP groups were reported 
(n=10/group; NS p < 0.05).  
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Figure 50 - Performance in Y-Maze test by PbS, PbI and PbP groups at 28 weeks 
There are no statistical differences between the lead exposed groups in % of spontaneous alternations (A) and total number 
of entries (B). Values are mean ± SEM. 
 
Episodic long-term memory assessment by NOR test performance of PbS, PbI and PbP groups 
at 28 weeks are shown in Figure 51. No significant differences were found between groups in the 
novelty recognition index calculated from the exploration time percentage data in the testing day 
(n=10/group; NS p > 0.05) as all groups show a similar pattern of exploration of the objects. 
 
Figure 51 - NOR test performance results in different phases of the test of the PbS, PbI and PbP groups at 28 weeks of age 
No significant differences between the three groups were found in the novelty recognition index (C) calculated from data in 
the testing day. Values are mean ± SEM. 
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Neuronal, synaptic and glial differences between lead exposed groups 
Intermittent lead exposure causes loss of synapses, the most prominent reactive microgliosis 
without differentiating in the neuronal number and astrogliosis 
 Figure 52 depicts differences in the immunohistochemistry data between PbP, PbS and PbI 
exposure protocols. NeuN stained tissues (A) show no significant differences between the three lead 
exposed groups, PbS, PbI and PbP (n=3/group; NS p > 0.05)). A significant decrease in the Syn staining 
(B) fluorescence intensity quantification was shown by the PbI group when compared to PbS (**p < 
0.01) and PbP group (**p < 0.01). The comparison of quantification of GFAP (C) and Iba-1 (D) showed 
that no significant differences were reported between groups in the number of astrocytes (NS p > 0.05) 
and a significant increase by the PbI group was reported when compared to the PbS group (*p < 0.05). 
 
Figure 52 - Quantification of NeuN, Syn, GFAP and Iba-1 in DG hippocampal area of PbS, PbI and PbP groups at 28 weeks. 
No differences were reported in NeuN positive cells between PbI and CTL groups (A). Significant decrease between PbI group 
and PbS and PbP groups were observed in the Syn staining quantification (B). The number of GFAP positive cells (C) showed 
to be similar between the three groups, however, an increase in the PbI group, when compared to the PbS group was 
reported in the number of Iba-1 positive (D). Values are mean ± SEM; *p < 0.05; **p < 0.01. 
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5 DISCUSSION 
The current comparative study provides additional insight into the association between the 
physiological dynamics and lead intoxication evoked by different profiles of lead exposure.  
First, independently of the type of lead exposure profile, the current study reveals a clear 
association between lead exposure, hypertension and cardio-respiratory reflex impairment. And, even 
after a lead free-period, only the sympathetic nervous system activity and the baroreflex function were 
re-established to physiological conditions. This pattern of association is similar with other clinical 
situations, such as hypertension, acute heart ischemia or heart failure46,119–121.  
Second, we have showed an involvement of sympathetic nervous system in modulation of the 
baroreceptor reflexes responses or hypertension development on lead intoxication. In fact, in our 
study, the overactivity of the sympathetic nervous system is concomitant with baroreceptor reflex 
impairment and/or hypertension. This exaggerated sympathetic tone associated with mild 
hypertension, observed in three different lead exposure profiles, can result from an increased intrinsic 
activity of the brain stem vasomotor neurons or can be secondary to a reduction of the inhibitory 
potency of baroreceptors 122,123. 
Third, all groups exposed to lead, evaluated in different time points, had behavioural changes, 
namely anxiety, hyperactivity and/or long-term impairment memory. This can be, in part, explained by 
the immunohistochemistry studies from the present study, that demonstrated that independently of 
lead exposure profile, lead-induced reactive astrogliosis and microgliosis in dentate gyrus of 
hippocampus of rats. 
Finally, in our model of intermittent exposure we demonstrated, for the first time, that an 
intermittent lead exposure causes adverse health effects, i.e, hypertension, sympathetic overactivity, 
increased chemoreflex sensitivity and baroreflex impairment, similar to a long-term exposure, however 
less pronounced.  
Therefore, exposures to lead during the developmental phase can alter the normal course of 
development, with lifelong health consequences. 
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I. Effects of different lead exposures on physiological parameters 
Increased blood pressure is synonymous of hypertension, which is one of the main causes of 
mortality and morbidity. It has been broadly defined that low-level lead exposure is one of the causes 
of hypertension in humans, and it has already been reproduced in various animal models of chronic 
lead exposure39,40,42,72.  
In the present study, all lead exposed rats showed an increased arterial blood pressure (≈ 15 
mmHg). In PbP group evaluated at 12, 20 and 28 weeks the average increase in systolic blood pressure 
was 37, 32, 51 mmHg and in diastolic blood pressure was 38, 51and 57 mmHg, respectively.  
In PbS and PbI groups evaluated at 20 weeks and in PbS group evaluated at 28 weeks it was an 
average increase in systolic blood pressure (66 and 36 mmHg, respectively) and in diastolic blood 
pressure (45 and 30 mmHg, respectively). Thus, during the 16 weeks period without lead exposure, a 
clearance of lead occurred with repercussions on blood pressure values. However, the effect on blood 
pressure values was similar to the PbS and PbI groups that only had 8 weeks without lead exposure. It 
remains to be determined if a clearance for a longer time can render these animal models’ 
normotensive.  
However, we can notice that, at 28 weeks, PbI group, the new animal model of lead exposure 
developed, has a less pronounced hypertension when compared to PbP group, which might suggest 
that the duration of Pb exposure is more relevant than the time of exposure.  In PbI group, the average 
increase in systolic blood pressure was 21 mmHg and in diastolic blood pressure was 18 mmHg. 
It is interesting that the effect on diastolic blood pressure produced by lead exposure was more 
evident than that of systolic blood pressure. The same pronounced effect on diastolic blood pressure 
was observed in men exposed to lead124. This can be explained by the fact that lead has a greater effect 
on the vascular smooth muscle, which contributes for peripheral resistance. Actuality, lead exposure 
affects the vascular response to vasoactive agents, induces endothelial damage, reducing the NO 
bioavailability and increasing endothelin levels125,126 .  
 The increase in blood pressure reported here has been well documented in previous studies 
using rodent models of chronic low levels of lead exposure40,42. An increase in blood pressure of rats 
occurs at low lead exposure levels of approximately 0.1 to 100 ppm, which is similar to the exposure 
levels seen in the environment. Similar observations were obtained in a population-based study, 
showing that blood lead levels as low as 20–30 µg/L increase blood pressure, even after adjustment for 
potential confounders such as age, sex, smoking habits, alcohol intake, waist circumference, and 
educational level127. Moreover, while low to moderate lead level exposures (BLLs <30 μg/dL) show only 
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a low degree of association with hypertension, higher exposures (primarily seen in occupational 
settings) increase the risk for hypertensive heart disease and cerebrovascular disease as latent 
effects128. 
Although the pathogenesis of hypertension promoted by lead is multifactorial, the mechanisms 
for lead-induced hypertension have been extensively examined. The involvement of renin-angiotensin 
and sympathetic nervous systems44,129, oxidative stress130, circulating catecholamine levels131, beta-
adrenergic receptors42, Na+/K+ ATPase39, and endothelial factors126 as well as renal dysfunction132 have 
been implicated in lead-induced hypertension.  
Despite the recorded hypertension evoked by different profiles of lead exposure, these animals 
did not have significant changes in heart rate when compared to controls. This leads us to conclude that 
neither early nor lifelong postnatal Pb exposure, at these doses, affect heart rate in adulthood. In 
contrast, others have shown that developmental exposure to other toxicants, such as manganese or 
mercury, can increase heart rate133,134. Studies in humans that evaluated heart rate showed inconsistent 
findings40. 
Regarding respiratory frequency, only the intermittent exposure (PbI group), evaluated at 28 
weeks) and the long-term exposure group (PbP) whose evaluation was performed at 12 and 28 weeks 
had an increase in respiratory frequency. This increase was concomitant with a higher chemoreceptor 
reflex sensitivity, indicating that lead triggered an overall alert-like reaction which could contribute not 
only to a higher respiratory rate, but also to blood pressure increase.  
In occupational lead exposure, it was established that workers have higher frequencies of 
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II. Effects of different lead exposures on cardio-respiratory reflexes 
All lead exposed groups had a higher chemoreceptor reflex sensitivity. However, it seems that 
PbP groups had a tendency of lower chemoreflex sensitivity that may be related to an already installed 
remodelling process due to a persistent stimulation which is not the case in the intermittent exposure 
(PbI). The PbS at 20 and 28 weeks and the PbI at 20 weeks, despite a lead-free period, didn’t show 
significant improvements in chemoreflex function.  
The permanent increased sensitivity to chemoreceptor reflex suggests the involvement of a 
protective sympathoexcitatory reflex in the maintenance of oxygen homeostasis but mostly appears to 
be an important piece of the internal defence mechanisms to manage the progression of lead 
toxicity136–138. 
Moreover, the observed chemoreflex facilitation was accompanied by the impairment of 
baroreflex function, a specific component of the defence reaction120,139,140, suggesting that lead toxicity 
may impair central autonomic areas leading to a higher sympathetic tone. The exception was PbS group 
that was exposed from foetal period until 12 weeks of age and then had 16 weeks period without lead 
exposure. Even the PbS and PbI groups that had 8 weeks period without lead exposure showed 
chemoreflex facilitation and baroreflex impairment. Thus, only a higher period without lead exposure 
is capable to improve baroreflex function, without significant changes in chemoreflex function. 
However, it is uncertain if a longer period (>16 weeks) without exposure could reverse the chemoreflex 
hypersensitivity. 
Therefore, our autonomic reflexes data indicate that lead exposure from foetal period, 
independently of the duration, induces a permanent chemoreceptor dysfunction and a temporary 
baroreceptor impairment that can be partially responsible for high blood pressure values. This 
dysfunction could have been evoked by the foetal exposure to lead, resulting in impairment of nervous 
system development.  
In fact, lead primarily affects the central nervous system, particularly the developing brain. 
During pregnancy, lead stored in bone is released into blood and, since lead has the ability to pass 
through the blood-brain barrier, it becomes a source of exposure to the developing foetus24,32. 
Additionally, children are at a greater risk than adults of suffering from the neurotoxic effects of lead, 
because they absorb 4 to 5 times as much ingested lead as adults from a given source1,24,141. This can 
result in lasting cognitive impairment , that has been already described previously in several prospective 
epidemiological studies32,142.  
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III. Effects of different lead exposures on autonomic nervous system 
To clarify the mechanisms underlying this autonomic reflex dysfunction, data from autonomic 
tone evaluation was essential. In fact, our data showed that the PbP exposed group have a lasting 
sympathoexcitation, which is in accordance with previous studies that indicated central and peripheral 
sympathetic hyperactivity after chronic lead exposure44,45. A study in 9-11-year-old children with low 
blood Pb levels (≤ 3.76 μg/dL) also found increased sympathetic nervous system activity during rest 
and, paradoxically, a depressed sympathetic response during the stressful computer task143. 
In fact, the PbP exposure, by stimulating the carotid chemoreflexes, induces sensory long-term 
facilitation, and drives an elevated sympathetic tone from the hindbrain leading to hypertension, and 
despite the 8-week period without lead exposure, the sympathetic activity in the PbS and PbI groups 
evaluated at 20 weeks does not diminish significantly. On the other hand, as shown by the results of 
the PbS group, a lead-free period of 16 weeks is sufficient for the reestablishment of the sympathetic 
nervous system activity, similar to the physiological condition. 
However, we can notice that, at 28 weeks, PbI group has a less pronounced sympathoexcitation 
when compared to PbP group, which might suggest that the duration of Pb exposure is more relevant 
than the time of exposure.   
The autonomic data from the present study indicates that the impaired autonomic regulation 
likely contributed to the baro and chemoreflex dysfunction observed in these Pb groups. Other studies 
already described that chronic lead exposure induces sympathoexcitation by peripheral and central 
stimulation, increasing the activity of sympathetic receptors (α2 and β1) and promoting increased 
plasma concentration of adrenaline and noradrenaline44.  
Sympathetic nervous activity is also affected by baroreceptor reflexes, as they provide a tonic 
inhibitory influence, controlling peripheral vasoconstriction and cardiac output144. Therefore, our data 
show that lead exposure, independently of the duration, induces a baroreceptor dysfunction that could 
be due to chronic resetting to hypertensive state. This dysfunction could have been evoked by the foetal 
exposure to lead experienced by all groups, resulting in impairment of nervous system development. 
Our hypothesis is that the autonomic dysfunction, seen in lead exposures, may have been 
mediated through central autonomic controls and the major mechanism inducing changes in 
cardiorespiratory reflexes would be similar to that already suggested for other pathologies, which also 
runs with sympathetic overexcitation, chemoreflex facilitation and baroreflex impairment46,119,121,131,145–
147. This mechanism may involve neuronal pathways linking the hypothalamus to lower brainstem 
nuclei, in particular, the PVN-NTS axis120,148,149. 
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IV. Different profiles of lead exposure and blood lead levels 
Blood lead levels, mainly lead levels in the erythrocytes, is representative of soft tissue lead and 
is the primary biomarker used for the assessment of lead exposure, both for screening and diagnostic 
purposes and for biomonitoring body burden and absorbed doses of the metal32. Other currently 
available biomarkers, such as bone or teeth (for past exposures), faeces (for current gastrointestinal 
exposure), or urine (for organic lead) are sometimes more useful than blood for the assessment of lead 
exposure32. In the study presented here, blood lead concentrations in PbS at 20 and 28 weeks and PbI 
rats at 20 weeks were much higher than those in control rats but lower than PbP rats (5.8±0.7 and 
3.7±0.4 versus 27.9±2.3 and 20.9±10.7 μg/dL, respectively). Despite the lower blood lead levels in PbI 
at 20 weeks and PbS at 20 and 28 weeks, caused by a lead-free period of 8 and 16 weeks, an elevation 
of blood pressure produced by these profiles of exposure was confirmed by the present investigation. 
Regarding the intermittent model of lead exposure (PbI), the blood lead levels, evaluated at 28 
weeks, were similar to those obtained in the group permanently exposed to lead, which might suggest 
that, in this type of lead exposure assessment, the time is more relevant than the duration of Pb 
exposure.   
Studies in humans, also demonstrated that immigrant women and children had elevated blood 
lead levels150,151. In refugee children, the levels were almost 14 times higher than that of US children 
aged 1–5 years based on the most recent National Health and Nutrition Examination Survey (NHANES) 
data. For that reason, the American Academy of Pediatrics recommends that children who have been 
adopted or emigrated from countries where lead poisoning is prevalent should be screened for 
elevated blood lead levels152. Considering the amount of lead acetate ingested, we would expect to get 
a higher increase in blood lead levels. The apparent reason for that is the standard chow used. This 
chow is rich in iron (0.18 g/Kg) that is known to decrease the susceptibility to lead toxicity, possibly 
through a lower lead absorption. The importance of an adequate iron diet was also demonstrated in a 
recent prospective study that showed that iron-deficient children in Boston aged 1–4 years were at 
significantly increased odds of developing lead poisoning153. 
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V. Effects of different lead exposures on neurobehavioral function 
Few studies have attempted to model neurobehavioral changes in young animals following low 
level exposure, and there is a needed to identify tests that are sensitive to the neurobehavioral changes 
that may occur. Mechanisms of action are not yet known; however, results have suggested that 
hippocampus/dentate gyrus may be uniquely vulnerable to early low-level lead exposure. 
Studies in children have suggested that many neurobehavioral functions are modified by early 
chronic low-level lead exposure. These include memory and learning, visual attention, abstract 
problem-solving, cognitive set-shifting, and motor dexterity68,154–161 . 
The results of the present study clearly demonstrate that lead exposure since foetal period, 
independently of the age or the lead exposure profile, produced a significant long-term anxiety-like 
behaviour in adult rats, as indicated by elevated plus-maze (EPM) test results, together with an increase 
in hippocampal astrocytes and microglial cells. It has already been shown that chronic lead exposure can 
produce behavioural disturbances, including anxiety, in human and in animal models85,162. Also, there 
is a strong evidence suggesting an association between hippocampal dysfunction and the behavioural 
deficiencies observed in experimental animals following neonatal Pb exposure57,81.  
In our results, we can notice that the young animals (12 weeks) were more anxious than the 
older ones (20 and 28 weeks). In fact, a study on the ontogeny of anxiety-like behaviour in laboratory 
healthy rodents has showed that adolescent rats demonstrated a higher anxiety-like response than 
adults163. The hypothesis that adolescent rats have a more noticeable response to stressors than adults 
is being confirmed by these results. 
Moreover, in the open field test (OFT), it was observed (although it was not shown in the 
results) that rats exposed to lead, independently of the exposure profile, spent more time exploring the 
periphery of the arena, usually in contact with the walls. This tendency to remain close the walls, called 
thigmotaxis, can be also used as an index of anxiety in rats. Even though, it is a normal rodent behaviour, 
animals showing a more prominent thigmotaxic behaviour are considered to be more anxious102. 
Also, a long-term lead exposure from foetal period until 20 weeks of age induces hyperactivity, 
showed by the increased average velocity, without changing the general locomotor activity and 
exploration behaviour. Studies within the past decade have indicated that certain environmental 
factors, including exposure to environmental pollutants can induce hyperactivity. Recent studies 
showed that Pb exposure may be associated with higher risk of clinically diagnosed ADHD in children, 
even at low levels164–168.  
Discussion 
90   |   Liana Shvachiy 
 
Although the PbS group also presented anxiety, it was less pronounced when compared to the 
permanently exposed group (PbP) or to the PbS and PbI groups evaluated at 20 weeks. This leads us to 
conclude that a 16 weeks lead-free period can cause beneficial behavioural effects by reducing the 
anxiety level. It remains to be determined if a longer lead-free period can render these animal models 
not anxious. 
As for the spatial memory and learning, no impairment was depicted, regardless the time or 
duration of exposure, as no alterations in the Y-Maze test results were observed. Regarding long-term 
memory, only the PbP evaluated at 12 weeks and the PbS and PbI evaluated at 20 weeks showed an 
impairment in NOR test performance, namely in Novelty index, as compared to controls. And this 
impairment of memory observed in the present study cannot be attributed to the locomotor activity 
impairment or anxiety behaviour presented by these animals, since it was similar to the matching 
control group. Therefore, anxiety was not a factor due to the long process of habituation to the arena 
of the Novel object recognition test. Moreover, anxiety and locomotor activity were also tested during 
the test, showing no differences between groups (data not shown in this thesis). 
However, although there were no significant differences in Novelty index results in the other 
exposed groups, we can notice that these animals had a similar exploration time in the two objects in 
the testing day of the NOR test (the novel and the familiar object), allowing us to conclude that they 
don´t recognize the new object as novelty. This, because, when animals are exposed to a familiar and a 
novel object, they approach frequently and spend more time exploring the novel than the familiar one 
due to animal’s normal explorative curiosity when in the presence of novelty, which was not the case 
in the Pb-exposed animals. 
This difference in NOR test performance can be due to lead-induced impairments of the 
hippocampus, in part explained by the synaptophysin, astrocytes and microglia expression in the dentate 
gyrus region. The PbS and PbI at 20 weeks and PbI at 28 weeks of age groups had a decrease in 
hippocampus/ dentate gyrus region synapses. The first, had a preeminent long-term memory 
impairment and the second had a similar exploration time in the two objects (indicative of some level 
of long-term memory impairment). Moreover, a permanent exposure until 20 weeks (PbP) promotes 
an increase in synapses in the dentate gyrus. Thus, lead exposure disturbs synaptogenesis of dentate 
gyrus, which could lead to synaptic plasticity impairment in the hippocampus.  
In fact, decreases and increases in the synaptic activity are an answer for synaptic strengthening 
or weakening over time, which has been given a name of synaptic plasticity. Synaptic plasticity in one 
of the main molecular processes behind learning and memory, and memories are being described by 
interconnected networks of synapses in the brain30,169. 
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Lead exposure has been already implicated in the impairment of synaptic plasticity in the 
developing hippocampus, but the mechanism remains unclear170. A reduction in the length of dendritic 
field and the number of dendritic branches of hippocampal dentate granule cells in the developing 
hippocampus after lead exposure has been reported171,172. Also, other studies have reported that 
developmental lead exposure causes alteration of NMDAR subunit ontogeny and disruption of its 
downstream signalling30,173, which are associated with deficits in hippocampal long-term potentiation 
(LTP)174. A more recent study concluded that developmental lead exposure alters synaptogenesis 
through inhibiting canonical Wnt pathway170. 
As the DG subregion of the hippocampus is a substrate for both cognition and mood 
regulation175, it was important to evaluate whether the different exposure profiles led to 
morphological48 alterations in this area. Immunohistochemistry evidence indicate that all exposed 
groups showed an increase in hippocampal astrocytes and microglial cells. Glial cells that englobe 
astrocytes and microglia in the CNS execute a variety of important functions, maintaining a complex 
interdependency between neurons and glia176.  Neuronal damage37 has been already described as one 
of the key elements of Pb toxicity. However, recently, neuroglia has been the focus as a target of low-
level lead exposure toxicity34.  
In our study, to better understand and correlate the changes that has been reported in animal 
behaviour with molecular alterations within the brain, more specifically, the cognitive impairment of 
the animals that have been exposed to lead, we focused our attention to both, neuronal and glial 
changes in the dentate gyrus. Astrocytes along with endothelial cells make up the blood brain barrier 
(BBB). Astrocytes perform homeostatic regulatory functions, exerting a fine control of the CNS 
extracellular environment, as well as, are one of the key elements of tripartite synapse. Also, astrocytes 
are involved in the long-term potentiation, that is crucial for synaptic plasticity, learning and 
memory116,118. Astrocytes play a crucial role in the inflammation induction in the brain, interplaying with 
microglia, upon antigen presence34,116. Also, upon pathological conditions, as lead toxicity, maladaptive 
reactive astrogliosis118 is triggered causing the depletion of glutamine, therefore reduction of synaptic 
GABA causing hyperexcitability of hippocampal neuronal circuits, due to a decrease in glutamine 
55,116,118. Glial fibrillary acidic protein (GFAP) is an astrocytic intermediate filament protein that is 
induced during periods of reactive astrocytic gliosis36.  
On a morphological level, reactive astrogliosis ranges from mild to prominent116,118, the last 
often being accompanied by glial scarring. In this study, the morphological evaluation of astrocytes, 
stained with GFAP in DG showed that exposure to lead enhanced the astrocytic reactivity, more 
specifically, a persistent maladaptive as GFAP immunoreaction was greatly enhanced within individual 
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cells, the density of the cells was much higher within the area and the branching processes of the cells 
were hypertrophic. To corroborate the morphological evaluation, a quantification of number of 
astrocytes within the area was performed as it has been already described that not only morphological 
changes, but also a number of astrocytes is increased upon lead exposure36,48.   
Our results showed that the developmental period of exposure to lead, from foetal period until 
12 weeks of age, leads to a strong reactive astrogliosis that persists through adulthood in all groups of 
exposed animals (permanent – PbP, intermittent – PbI and single exposure – PbS). Exposure to lead 
during adulthood does not cause changes in the astrogliosis, which persists reactive through time, even 
of the absence of exposure is of 16 weeks (PbS group). These findings are consistent with other that 
reported1 that the major lifelong changes in the GFAP gene expression occur during the developmental 
period, due to immaturity of blood-brain barrier, offering little protection and low resistance to lead 
toxicity  because of the lack of high-affinity  lead-binding protein in astrocytes that sequester lead and 
remove it from mitochondria177.  
Nevertheless, GFAP is the major marker of astrocytes, studies showed that it is not exclusively 
produced by astrocytes, but also is present, in very small quantities in oligodendrocytes, that are 
responsible for neuronal myelinisation. The demyelination of neurons has been already described as 
one of the major toxicological changes due to lead exposure178. Thus, the changes in the GFAP 
expression may reflect various glial populations that respond differently to Pb.  
Microglial cells are the neuroinflammatory sensors and are usually present in the resting state 
in the brain. Studies have already confirmed that, microglia, morphologically, are defined as extremely 
motile cells with processes and branches for territorial scanning in the brain117,179. In the pathogen 
presence, microglia are activated, becoming reactive microglia, changing morphologically to an 
ameboid form and increasing in number of cells substance release to combat the pathogenic attack. 
These substances could also be damaging to the surroundings of the activated microglia, leading to 
oxidative stress. The migrating nature of these cells permits a rapid response to the injury in the nervous 
system, thus leading to the fast proliferation and phagocyting of the cells and their parts179. Iba1 
(ionizing calcium-binding adaptor molecule 1) has been already described by various studies as being a 
novel protein that it is singly expressed in microglia and its upregulation is a marker of activation of 
these cells. This polyclonal antibody does not cross-react with neurons or astrocytes180.  
Morphological evaluation of animals at 20 weeks showed that exposure to lead until 12 weeks 
of age and exposure to lead until 20 weeks of age does not disrupt the microglial cells in the dentate 
gyrus, presenting microglial cells with a small cell bodies and branching processes for territorial 
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scanning. However, the results from quantification of the Iba-1 stained tissue showed that an increase 
in the number of resting state microglial cells was provoked by exposure to lead from foetal period until 
adulthood (PbP group observations). This is consistent with other results observed before that show 
that due to the changes in the neurogenesis, and the fact that lead is present in the brain, increase in 
the number of microglial cells happens55,181. This increase persists even after a long abstinence from 
lead exposure, which was observed in the PbS group of animals.   
Remarkably, a different pattern of microgliosis was observed in the animals that were exposed 
to lead twice (PbI group, from foetal to 12 weeks of age and from 20 to 28 weeks of age). After the 
second exposure to lead, the microglia was activated, with branching loss and upregulation to Iba-1 
staining. Also, an increase in the number of cells from 20 to 28 weeks was observed which is indicative 
of not only disruption of microglia but also a process of neuroinflammation in the dentate gyrus, causing 
cognitive and behavioural changes in animals. This activation is consistent with other results that show 
that neuroinflammation is one of the key features of lead toxicity34. Together with activation of 
astroglia, the intermittent exposure to lead causes the neuroinflammatory activation, delaying their 
promoting assistance in the neuronal differentiation and maturation in the hippocampus, a specific 
brain region that maintains active neurogenesis and prevents neurodegeneration in whole life.  
It is important to mention that all the neurobehavioral impairments observed in the present 
study were not the result of nonspecific stimulation. In fact, the different lead exposures did not affect 
body weight gain of dams or offspring development, neither locomotor activity. 
Changes in long-term memory that have been identified in the lead exposed animals are one 
of the main neurobehavioral disruptions that have the most devastating effects during the lifetime of 
the brain health. The early alterations in the hippocampus (and more specifically in the dentate gyrus) 
are the potential mechanisms for neural pathways formation disruptions182 , memory dysfunction, 
learning impairment during development and weakened neurogenesis during adulthood and aging183. 
All these alterations have been already linked to an increase in vulnerability to cognitive decline, 
neurodegenerative diseases and dementia157,184. 
The neurobehavioral results presented here are not surprising, since exposure to lead began in 
a very critical period, the foetal period, and the primary site of Pb action is the central nervous system, 
where Pb exposure is associated with several neurobehavioral and psychological alterations19,58,185,186. 
During the prenatal period in mammalian species, the rapid growth of the central nervous system 
makes the foetus particularly vulnerable to insults187,188. This phenomenon is evident from the results 
of several independent (and prospective) human studies which indicate that maternal stress during 
pregnancy is associated with adverse neurodevelopmental outcomes in the child later in life, including 
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attention-deficit/hyperactivity disorder, autism, and anxiety disorders188. Also, in low-level exposure to 
lead during early childhood was shown to be inversely associated with neuropsychological development 
and neurobehavioral-cognitive performance189. 
Similar to human studies, the current research in animals exposed to different lead profiles has 
clearly demonstrated that behavioural changes, namely anxiety, hyperactivity and/or long-term 
impairment memory can be a consequence of developmental lead exposure.  
Therefore, the lead-induced alterations in rat development observed here due to ingestion of 
lead water (the most common route of contamination in the general population) are important in terms 
of searching for similar developmental alterations in human beings exposed to low levels of lead.  
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6 CONCLUSIONS AND FUTURE PERSPECTIVES 
As the result of this work, we provide the first direct experimental evidence that an intermittent 
lead exposure has detrimental effects on cardiorespiratory control, on anxiety, cognitive impairment 
and on synaptic, astrocytic and microglial functions. The current work adds to our understanding of the 
complex interactions between sex, level of Pb exposure and developmental window of Pb exposure on 
cognitive processing and mammals´ physiology. 
In summary, our experiments have provided several main findings to support our hypothesis 
that the exposure in utero produces behavioural, functional, and structural deficits that can be 
irreversible as they were apparent, in this study, at adult age.  
As future perspectives, we intend to evaluate the effect of different lead exposure profiles, in 
target organs already removed and where lead is primarily distributed, such as heart, liver and kidneys. 
Also, correlations between target organs lead levels, blood lead levels, lead exposure profiles and 
physiological and neurobehavioral parameters should be performed. 
In order to evaluate the physiological changes through the time course of animal lives, 
telemetric sensors should be implanted for continuous haemodynamic assessment of these subjects to 
better understand the most relevant timepoints of lead toxicological effects in conscious animals. 
Moreover, since the chemoreflex dysfunction and anxiety behaviour were maintained after a 
16 week-period without lead exposure, future pharmacological studies in central areas should be tested 
in order to reverse these dysfunctions towards normality.  
Other central brain regions should also be evaluated, specially the amygdala, hypothalamus 
and centres of autonomic regulation for traces of morphofunctional changes within these areas that 
could account for the alterations that were observed in the animal models in this study. Similarly, some 
other studies must be performed to assess neurogenesis and neural morphological alterations, possible 
myelinic loss, electrophysiological alterations and other behavioural changes that lead could be 
responsible for within various lead exposure protocols. 
Since sex differences in the neurodevelopmental effects of early lead exposure have been 
reported in humans, future research should focus on health effects differences between males and 
females exposed to different lead exposure profiles.  
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